# EDGAR Filing Document

**Accession Number:** 0000921582
**File Stem:** 0001628280-26-028960
**Filing Date:** 2026-4
**Character Count:** 271330
**Document Hash:** 93d65f517c65cd1615b3efc7c9a61641
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-028960.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0001628280-26-028960

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 105

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IMAX CORP
- **CENTRAL INDEX KEY:** 0000921582
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHOTOGRAPHIC EQUIPMENT & SUPPLIES [3861]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 980140269
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35066
- **FILM NUMBER:** 26926521

**BUSINESS ADDRESS:**
- **STREET 1:** 2525 SPEAKMAN DRIVE
- **CITY:** MISSISSAUGA
- **STATE:** A6
- **ZIP:** L5K 1B1
- **BUSINESS PHONE:** 9054036500

**MAIL ADDRESS:**
- **STREET 1:** 2525 SPEAKMAN DRIVE
- **CITY:** MISSISSAUGA
- **STATE:** A6
- **ZIP:** L5K 1B1

?xml version='1.0' encoding='ASCII'? imax-20260331

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**Form 10-Q**

**(Mark One)**

**☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026**

**OR**

**☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to**

**Commission File Number 001-35066**

**IMAX Corporation**

*(Exact name of registrant as specified in its charter)*

---

| | |
|:---|:---|
| **Canada**  | **98-0140269** |
| (State or other jurisdiction of <br>incorporation or organization) | *(I.R.S. Employer*<br>*Identification Number)* |
| **2525 Speakman Drive,**<br>**Mississauga, Ontario, Canada L5K 1B1**<br>**(905) 403-6457** | **902 Broadway, Floor 20**<br>**New York, New York, USA 10010**<br>**(212) 821-0142** |

---

*(Address of principal executive offices, zip code, telephone numbers)*

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Shares, no par value** | **IMAX** | **The New York Stock Exchange** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

---

| | |
|:---|:---|
| **Class** | **Outstanding as of March 31, 2026** |
| Common Shares, no par value | 54,855,176 |

---

------

**IMAX CORPORATION**

**Table of Contents**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| **<u>[PART I. FINANCIAL INFORMATION](#id379d5ed014540febbf2b68577b6e60b_10)</u>** | **<u>[PART I. FINANCIAL INFORMATION](#id379d5ed014540febbf2b68577b6e60b_10)</u>** | |
| Item 1. | <u>[Financial Statements](#id379d5ed014540febbf2b68577b6e60b_16)</u> | <u>[3](#id379d5ed014540febbf2b68577b6e60b_16)</u> |
| Item 2. | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#id379d5ed014540febbf2b68577b6e60b_439)</u> | <u>[35](#id379d5ed014540febbf2b68577b6e60b_439)</u> |
| Item 3. | <u>[Quantitative and Qualitative Disclosures about Market Risk](#id379d5ed014540febbf2b68577b6e60b_571)</u> | <u>[54](#id379d5ed014540febbf2b68577b6e60b_571)</u> |
| Item 4. | <u>[Controls and Procedures](#id379d5ed014540febbf2b68577b6e60b_595)</u> | <u>[55](#id379d5ed014540febbf2b68577b6e60b_595)</u> |
| **<u>[PART II. OTHER INFORMATION](#id379d5ed014540febbf2b68577b6e60b_604)</u>** | **<u>[PART II. OTHER INFORMATION](#id379d5ed014540febbf2b68577b6e60b_604)</u>** |  |
| Item 1. | <u>[Legal Proceedings](#id379d5ed014540febbf2b68577b6e60b_607)</u> | <u>[57](#id379d5ed014540febbf2b68577b6e60b_607)</u> |
| Item 1A. | <u>[Risk Factors](#id379d5ed014540febbf2b68577b6e60b_610)</u> | <u>[57](#id379d5ed014540febbf2b68577b6e60b_610)</u> |
| Item 2. | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#id379d5ed014540febbf2b68577b6e60b_613)</u> | <u>[59](#id379d5ed014540febbf2b68577b6e60b_613)</u> |
| Item 5. | <u>[Other Information](#id379d5ed014540febbf2b68577b6e60b_616)</u> | <u>[59](#id379d5ed014540febbf2b68577b6e60b_616)</u> |
| Item 6. | <u>[Exhibits](#id379d5ed014540febbf2b68577b6e60b_622)</u> | <u>[60](#id379d5ed014540febbf2b68577b6e60b_622)</u> |
| <u>[Signatures](#id379d5ed014540febbf2b68577b6e60b_625)</u> | <u>[Signatures](#id379d5ed014540febbf2b68577b6e60b_625)</u> | <u>[61](#id379d5ed014540febbf2b68577b6e60b_625)</u> |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**IMAX CORPORATION**

**PART I. FINANCIAL INFORMATION**

**Item 1.&nbsp;&nbsp;&nbsp;&nbsp;*Financial Statements***

---

| | |
|:---|:---|
| | **Page** |
| The following unaudited Condensed Consolidated Financial Statements are filed as part of this Report: |  |
| <u>[Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025](#id379d5ed014540febbf2b68577b6e60b_19)</u> | <u>[4](#id379d5ed014540febbf2b68577b6e60b_19)</u> |
| <u>[Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 2025](#id379d5ed014540febbf2b68577b6e60b_22)</u> | <u>[5](#id379d5ed014540febbf2b68577b6e60b_22)</u> |
| <u>[Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2026 and 2025](#id379d5ed014540febbf2b68577b6e60b_25)</u> | <u>[6](#id379d5ed014540febbf2b68577b6e60b_25)</u> |
| <u>[Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025](#id379d5ed014540febbf2b68577b6e60b_28)</u> | <u>[7](#id379d5ed014540febbf2b68577b6e60b_28)</u> |
| <u>[Condensed Consolidated Statements of Shareholders' Equity for the three months ended March 31, 2026 and 2025](#id379d5ed014540febbf2b68577b6e60b_8246337211484)</u> | <u>[8](#id379d5ed014540febbf2b68577b6e60b_8246337211484)</u> |
| <u>[Notes to Condensed Consolidated Financial Statements](#id379d5ed014540febbf2b68577b6e60b_34)</u> | <u>[9](#id379d5ed014540febbf2b68577b6e60b_34)</u> |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**IMAX CORPORATION**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

*(In thousands of U.S. Dollars, except share amounts)* 

*(Unaudited)*

---

| | | |
|:---|:---|:---|
| | **March 31,** | **December 31,** |
| | **2026** | **2025** |
| **Assets** |  |  |
| Cash and cash equivalents | $145995 | $151168 |
| Accounts receivable, net of allowance for credit losses | 108540 | 108079 |
| Financing receivables, net of allowance for credit losses | 121325 | 121954 |
| Variable consideration receivables, net of allowance for credit losses | 90624 | 91402 |
| Inventories | 35823 | 32505 |
| Prepaid expenses | 16663 | 14881 |
| Film assets, net of accumulated amortization | 16638 | 15529 |
| Property, plant and equipment, net of accumulated depreciation | 240890 | 242910 |
| Lease incentives and other assets | 27240 | 24820 |
| Deferred income tax assets, net of valuation allowance | 12675 | 12577 |
| Goodwill | 45815 | 45815 |
| Other intangible assets, net of accumulated amortization | 30923 | 32391 |
| **Total assets** | $**893151** | $**894031** |
| **Liabilities** |  |  |
| Accounts payable | $17193 | $19478 |
| Accrued and other liabilities | 88138 | 105293 |
| Deferred revenue | 56132 | 50395 |
| Revolving credit facility borrowings, net of unamortized debt issuance costs | 46702 | 34577 |
| Convertible notes and other borrowings, net of unamortized discounts and debt issuance costs | 244128 | 244034 |
| Deferred income tax liabilities | 12521 | 12521 |
| **Total liabilities** | **464814** | **466298** |
| **Commitments, contingencies and guarantees** (see Note 7) |  |  |
| **Non-controlling interests** | **691** | **666** |
| **Shareholders' equity** |  |  |
| &nbsp;&nbsp;&nbsp;Capital stock common shares — no par value. Authorized — Unlimited number. <br>54,855,176 issued and outstanding (December 31, 2025 — 53,921,676 issued and outstanding) | 429650 | 419162 |
| Other equity | 145998 | 164782 |
| Statutory surplus reserve | 4219 | 4219 |
| Accumulated deficit | (235741) | (239967) |
| Accumulated other comprehensive loss | (8664) | (10305) |
| **Total shareholders' equity attributable to common shareholders** | **335462** | **337891** |
| Non-controlling interests | 92184 | 89176 |
| **Total shareholders' equity** | **427646** | **427067** |
| **Total liabilities and shareholders' equity** | $**893151** | $**894031** |
| *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**IMAX CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

*(In thousands of U.S. Dollars, except per share amounts)* 

*(Unaudited)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| | **2026** | **2025** |
| **Revenues** |  |  |
| Technology sales | $13414 | $13524 |
| Image enhancement and maintenance services | 48584 | 50753 |
| Technology rentals | 16624 | 19311 |
| Finance income | 2757 | 3079 |
|  | **81379** | **86667** |
| **Costs and expenses applicable to revenues** |  |  |
| Technology sales | 5556 | 7223 |
| Image enhancement and maintenance services | 22936 | 19445 |
| Technology rentals | 7076 | 6823 |
|  | **35568** | **33491** |
| **Gross margin** | **45811** | **53176** |
| Selling, general and administrative expenses | 32488 | 33462 |
| Research and development | 1804 | 1318 |
| Amortization of intangible assets | 2028 | 1731 |
| Credit loss reversal, net | (460) | (126) |
| Restructuring charges and other impairments |  | 57 |
| **Income from operations** | **9951** | **16734** |
| Realized and unrealized investment gains | 36 | 32 |
| Retirement benefits non-service expense | (67) | (70) |
| Interest income | 468 | 540 |
| Interest expense | (1896) | (1801) |
| **Income before taxes** | **8492** | **15435** |
| Income tax expense | (2421) | (7285) |
| **Net income** | **6071** | **8150** |
| Net income attributable to non-controlling interests | (1845) | (5823) |
| **Net income attributable to common shareholders** | $**4226** | $**2327** |
| **Net income per share attributable to common shareholders:** |  |  |
| Basic | $0.08 | $0.04 |
| Diluted | $0.07 | $0.04 |
| **Weighted average shares outstanding (in thousands):** |  |  |
| Basic | 54125 | 53145 |
| Diluted | 56392 | 54969 |
| *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**IMAX CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

*(In thousands of U.S. Dollars)* 

*(Unaudited)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| | **2026** | **2025** |
| **Net income** | $**6071** | $**8150** |
| **Other comprehensive income before tax** |  |  |
| &nbsp;&nbsp;Unrealized net loss from cash flow hedging instruments | (631) | (715) |
| &nbsp;&nbsp;Realized net (gain) loss from cash flow hedging instruments | (342) | 1335 |
| &nbsp;&nbsp;Foreign currency translation adjustments | 3885 | 421 |
| &nbsp;&nbsp;Amortization of defined benefit and postretirement benefit plans net gain | (167) | (205) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total other comprehensive income before tax** | **2745** | **836** |
| Income tax recovery related to other comprehensive income |  | (109) |
| Other comprehensive income, net of tax | 2745 | 727 |
| **Comprehensive income** | **8816** | **8877** |
| Comprehensive income attributable to non-controlling interests | (2949) | (5944) |
| **Comprehensive income attributable to common shareholders** | $**5867** | $**2933** |
| *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**IMAX CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

*(In thousands of U.S. Dollars)* 

*(Unaudited)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| | **2026** | **2025** |
| **Operating Activities** |  |  |
| Net income | $6071 | $8150 |
| Adjustments to reconcile net income to cash provided by operating activities: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 15236 | 14913 |
| &nbsp;&nbsp;Amortization of deferred financing costs | 528 | 492 |
| &nbsp;&nbsp;Credit loss reversal, net | (460) | (126) |
| &nbsp;&nbsp;Write-downs, including asset impairments | 57 | 193 |
| &nbsp;&nbsp;Deferred income tax recovery | (35) |  |
| &nbsp;&nbsp;Share-based and other non-cash compensation | 5792 | 5275 |
| &nbsp;&nbsp;Unrealized foreign currency exchange loss | 83 | 289 |
| &nbsp;&nbsp;Realized and unrealized investment gain | (36) | (32) |
| Changes in assets and liabilities: |  |  |
| &nbsp;&nbsp;Accounts receivable | (751) | (15014) |
| &nbsp;&nbsp;Inventories | (3355) | 1032 |
| &nbsp;&nbsp;Film assets | (5353) | (7396) |
| &nbsp;&nbsp;Lease incentives provided to exhibitor customers | (8671) | (1029) |
| &nbsp;&nbsp;Deferred revenue | 5769 | 1390 |
| &nbsp;&nbsp;Changes in other operating assets and liabilities | (10846) | (1186) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by operating activities** | **4029** | **6951** |
| **Investing Activities** |  |  |
| Purchase of property, plant and equipment | (2132) | (1645) |
| Investment in equipment for joint revenue sharing arrangements | (4003) | (11746) |
| Acquisition of other intangible assets | (792) | (1233) |
| &nbsp;&nbsp;**Net cash used in investing activities** | **(6927)** | **(14624)** |
| **Financing Activities** |  |  |
| Revolving credit facility borrowings | 31000 | 23000 |
| Repayments of revolving credit facility borrowings | (19000) | (10000) |
| Debt issuance costs related to convertible notes | (944) |  |
| Credit facility amendment fees paid | (9) |  |
| Repayments of other borrowings | (164) | (209) |
| Taxes withheld and paid on employee stock awards vested | (17451) | (9505) |
| Common shares issued - stock options exercised | 3806 | 948 |
| &nbsp;&nbsp;**Net cash (used in) provided by financing activities** | **(2762)** | **4234** |
| Effects of exchange rate changes on cash | 487 | (84) |
| **Decrease in cash and cash equivalents during period** | **(5173)** | **(3523)** |
| **Cash and cash equivalents, beginning of period** | **151168** | **100592** |
| **Cash and cash equivalents, end of period** | $**145995** | $**97069** |
| *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**IMAX CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY**

*(In thousands of U.S. Dollars, except share data)* 

*(Unaudited)*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
| | | | | | | **Accumulated Other Comprehensive Loss** | | **Total Shareholders' Equity** |
| | **Capital Stock** | **Capital Stock** | | **Statutory Surplus Reserve** | **Accumulated Deficit** | **Accumulated Other Comprehensive Loss** | **Non-controlling Interests** | **Total Shareholders' Equity** |
| | **Shares** | **Amount** |<br>**Other Equity** | **Statutory Surplus Reserve** | **Accumulated Deficit** | **Accumulated Other Comprehensive Loss** | **Non-controlling Interests** | **Total Shareholders' Equity** |
| Balance as of December 31, 2025 | 53921676 | $419162 | $164782 | $4219 | $(239967) | $(10305) | $89176 | $427067 |
| &nbsp;&nbsp;Restricted share units and performance stock units vested, net of shares withheld for employee tax obligations | 812277 | 5710 | (22993) |  |  |  |  | $(17283) |
| &nbsp;&nbsp;Employee stock options exercised, net of shares withheld for employee tax obligations | 121223 | 4778 | (972) |  |  |  |  | $3806 |
| &nbsp;&nbsp;Amortization of share-based payment expense - restricted share units and performance stock units |  |  | 5181 |  |  |  | 84 | $5265 |
| &nbsp;&nbsp;Net income |  |  |  |  | 4226 |  | 1820 | $6046 |
| &nbsp;&nbsp;Other comprehensive income, net of tax |  |  |  |  |  | 1641 | 1104 | $2745 |
| Balance as of March 31, 2026 | 54855176 | $429650 | $145998 | $4219 | $(235741) | $(8664) | $92184 | $427646 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| | | | | | | **Accumulated Other Comprehensive Loss** | | **Total Shareholders' Equity** |
| | **Capital Stock** | **Capital Stock** | | **Statutory Surplus Reserve** | **Accumulated Deficit** | **Accumulated Other Comprehensive Loss** | **Non-controlling Interests** | **Total Shareholders' Equity** |
| | **Shares** | **Amount** |<br>**Other Equity** | **Statutory Surplus Reserve** | **Accumulated Deficit** | **Accumulated Other Comprehensive Loss** | **Non-controlling Interests** | **Total Shareholders' Equity** |
| Balance as of December 31, 2024 | 52946200 | $401420 | $185268 | $4051 | $(274675) | $(16598) | $78069 | $377535 |
| &nbsp;&nbsp;Restricted share units and performance stock units vested, net of shares withheld for employee tax obligations | 751817 | 11380 | (20942) |  |  |  |  | $(9562) |
| &nbsp;&nbsp;Employee stock options exercised, net of shares withheld for employee tax obligations | 44031 | 1241 | (293) |  |  |  |  | $948 |
| &nbsp;&nbsp;Amortization of share-based payment expense - restricted share units and performance stock units |  |  | 5718 |  |  |  | 93 | $5811 |
| &nbsp;&nbsp;Change in statutory surplus reserve, IMAX China |  |  |  | 55 | (55) |  |  | $— |
| &nbsp;&nbsp;Net income |  |  |  |  | 2327 |  | 5827 | $8154 |
| &nbsp;&nbsp;Other comprehensive income, net of tax |  |  |  |  |  | 606 | 121 | $727 |
| Balance as of March 31, 2025 | 53742048 | $414041 | $169751 | $4106 | $(272403) | $(15992) | $84110 | $383613 |
| *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* | *(See the accompanying notes, which are an integral part of these Condensed Consolidated Financial Statements.)* |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**IMAX CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

*(Tabular amounts in thousands of U.S. Dollars, unless otherwise stated)* 

**1. Basis of Presentation**

***Accounting Principles***

IMAX Corporation (together with its subsidiaries, unless the context requires otherwise, the "Company" or "IMAX"), prepares financial statements in accordance with United States Generally Accepted Accounting Principles ("U.S. GAAP" or "GAAP") and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures have been condensed or omitted as permitted by such rules and regulations. In the opinion of the Company's management, the unaudited Condensed Consolidated Financial Statements reflect all necessary adjustments for a fair statement of interim results. The Condensed Consolidated Balance Sheet at December 31, 2025 was derived from the Company's audited annual Consolidated Financial Statements in the Company's 2025 Annual Report on Form 10-K (the "2025 Form 10-K"). The interim results presented in the Company's Condensed Consolidated Statements of Operations and Condensed Consolidated Statements of Cash Flows are not necessarily indicative of results for a full year. Certain prior period comparatives have been revised to conform with the current period presentation.

These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements in the 2025 Form 10-K, which includes significant accounting policies adopted by the Company.

***Principles of Consolidation***

These unaudited Condensed Consolidated Financial Statements include the accounts of IMAX together with its consolidated subsidiaries, except for subsidiaries which have been identified as variable interest entities ("VIEs") where the Company is not the primary beneficiary. All intercompany accounts and transactions have been eliminated. The Company has evaluated its various variable interests to determine whether they are VIEs as required by U.S. GAAP.

The Company has interests in ten film production companies, which have been identified as VIEs. The Company is the primary beneficiary of and consolidates five of these entities as it has the power to direct the activities that most significantly impact the economic performance of the VIE, and it has the obligation to absorb losses or the right to receive benefits from the respective VIE that could potentially be significant. The majority of the assets relating to these production companies are held by the IMAX Original Film Fund (the "Original Film Fund"). The Company does not consolidate the other five film production companies because it does not have the power to direct their activities and it does not have the obligation to absorb the majority of the expected losses or the right to receive expected residual returns. The Company uses the equity method of accounting for these entities, which continues to not be material to the Company's Condensed Consolidated Financial Statements. A change in the value of an equity method investment that is other than temporary is recognized in the Condensed Consolidated Statements of Operations.

As of March 31, 2026 and December 31, 2025, total assets and liabilities of the Company's consolidated VIEs were as follows:

---

| | | |
|:---|:---|:---|
| | **March 31,** | **December 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Total assets | $1783 | $1746 |
| Total liabilities | $363 | $362 |

---

***Estimates and Assumptions***

In preparing the Company's Condensed Consolidated Financial Statements, management makes judgments in applying various accounting policies. The areas of policy judgment are consistent with those reported in Note 2 of the Company's audited Consolidated Financial Statements included in its 2025 Form 10-K. The significant estimates made by management include, but are not limited to: (i) the allocation of the transaction price in an IMAX System arrangement to distinct performance obligations; (ii) the amount of variable consideration to be earned on sales of IMAX Systems based on projections of future box office performance and inflation; (iii) expected credit losses on accounts receivable, financing receivables, and variable consideration receivables; (iv) provisions for the write-down of excess and obsolete inventories; (v) the fair values of the reporting units used in assessing the recoverability of goodwill; (vi) the cash flow projections used in testing the recoverability of long-lived assets such as the system equipment supporting joint revenue sharing arrangements ("JRSAs"); (vii) the economic lives of the system equipment supporting joint revenue sharing arrangements; (viii) the useful lives of tangible and intangible assets; (ix) the ultimate revenue forecasts used to test the recoverability of film assets; (x) the discount rates used to determine the present value of financing receivables, variable consideration and lease

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

liabilities, as well as to determine the fair values of the Company's reporting units for the purpose of assessing the recoverability of goodwill; (xi) pension plan assumptions; (xii) estimates related to the fair value and projected vesting of share-based payment awards; (xiii) the valuation allowance of deferred income tax assets; and (xiv) reserves related to uncertain tax positions.

**2. New Accounting Standards and Accounting Changes**

***Adoption of New Accounting Pronouncements***

*Measurement of Credit Losses for Accounts Receivable and Contract Assets*

In July 2025, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2025-05, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets ("ASU 2025-05"). The amendments in ASU 2025-05 provide a practical expedient that allows entities to assume current economic conditions as of the balance sheet date will remain unchanged throughout the reasonable and supportable forecast period when estimating expected credit losses for eligible financial assets, including trade receivables and contract assets. The Company adopted ASU 2025-05 for the three months ended March 31, 2026. The adoption did not have a material impact on its Condensed Consolidated Financial Statements.

***Recently Issued FASB Accounting Standards Codification Updates Not Yet Adopted***

*Disaggregation of Income Statement Expenses*

In November 2024, the FASB issued ASU No. 2024-03, "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures" ("ASU 2024-03"). The amendments in ASU 2024-03 expand disclosures about specific expense categories presented on the face of the income statement and addresses requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation and amortization) in commonly presented expense captions (such as cost of sales, selling, general and administrative expenses). ASU 2024-03 is effective for interim periods within annual reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is in the process of evaluating the impact of ASU 2024-03 on its Consolidated Financial Statements.

*Targeted Improvements to the Accounting for Internal-Use Software*

In September 2025, the FASB issued ASU No. 2025-06, "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software ("ASU 2025-06"). The amendments in ASU 2025-06 clarify and refine the criteria for capitalizing costs related to internal-use software. Under the new guidance, capitalization is permitted when both of the following conditions are met: (i) management has authorized and committed to funding the software project, and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for fiscal periods beginning after December 15, 2027, and interim periods thereafter. The Company is in the process of evaluating the impact of this ASU on its Consolidated Financial Statements.

*Hedge Accounting Improvements*

In November 2025, the FASB issued ASU No. 2025-09, "Derivatives and Hedging (Topic 815): Hedge Accounting Improvements" ("ASU 2025-09"). The amendments in ASU 2025-09 more closely align hedge accounting with the economics of an entity's risk management activities for (i) similar risk assessment for cash flow hedges, (ii) hedging forecasted interest payment on choose-your-rate debt instruments, (iii) cash flow hedges of nonfinancial forecasted transactions, (iv) net written options as hedging instruments, and (v) foreign-currency-denominated debt instrument as hedging instrument and hedged item. ASU 2025-09 is effective for fiscal periods beginning after December 15, 2026, and interim periods thereafter. The Company is in the process of evaluating the impact of this ASU on its Consolidated Financial Statements.

*Accounting for Government Grants Received by Business Entities*

In December 2025, the FASB issued ASU No. 2025-10, "Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities" ("ASU 2025-10"). The amendments in ASU 2025-10 establishes accounting and guidance for a government grant received by an entity. Under the new guidance, a government grant is not recognized until it is probable that an entity will comply with the conditions attached to the grant and the grant will be received, and recognition guidance is met. A grant related to an asset is recognized on the balance sheet as an entity incurs the related costs for which the grant is intended to compensate. ASU 2025-10 is effective for fiscal periods beginning after December 15, 2028, and interim periods thereafter. The Company is in the process of evaluating the impact of this ASU on its Consolidated Financial Statements.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

The Company considers the applicability and impact of all recently issued FASB accounting standard codification updates. ASUs that are not noted above were assessed and determined to be not applicable or not significant to the Company's Condensed Consolidated Financial Statements for the period ended March 31, 2026.

**3. Receivables**

The ability of the Company to collect its receivables is principally dependent on the viability and solvency of individual theater operators which is significantly influenced by consumer behavior and general economic conditions. Theater operators, or other customers, may experience financial difficulties that could result in them being unable to fulfill their payment obligations to the Company.

In order to mitigate the credit risk associated with the Company's receivables, management performs an initial credit evaluation prior to entering into an arrangement with a customer and then regularly monitors the credit quality of each customer through an analysis of collections history and aging. This monitoring process includes meetings on at least a monthly basis to identify credit concerns and potential changes in credit quality classification. A customer may improve their credit quality classification once a substantial payment is made on an overdue balance or when the customer has agreed to a payment plan and payments have commenced in accordance with that plan. Changes in credit quality classification are dependent upon management approval. The Company's internal credit quality classifications are reported in Note 4 of the Company's audited Consolidated Financial Statements included in its 2025 Form 10-K.

During the period when the accretion of Finance Income is suspended for Financing Receivables, any payments received from a customer are applied against the outstanding balance owed. If payments are sufficient to cover any unreserved receivables, a reversal of the provision is recorded to the extent of the residual cash received. Once the collectability issues are resolved and the customer has returned to being in good standing, the Company will resume recognition of Finance Income.

When a customer's aging exceeds 90 days, the Company's policy is to perform an enhanced review to assess collectability of the theater's past due accounts. The over 90 days past due category may be an indicator of potential impairment as up to 90 days outstanding is considered to be a reasonable time to resolve any issues.

The Company develops an estimate of expected credit losses by class of receivable and customer type through a calculation that utilizes historical loss rates, which are then adjusted for specific receivables that are judged to have a higher-than-normal risk profile after considering management's internal credit quality classifications. Additional credit loss provisions are also recorded taking into account macro-economic and industry risk factors. The write-off of any billed receivable balance requires the approval of management.

Management's judgments regarding expected credit losses are based on the facts available to management and involve estimates about the future. As a result, the Company's judgments and associated estimates of credit losses may ultimately prove, with the benefit of hindsight, to be incorrect. The impacts of inflation, and rising interest rates may impact future credit losses. The Company will continue to monitor economic trends and conditions and portfolio performance and adjust its allowance for credit loss accordingly.

*Accounts Receivable*

Accounts receivable principally includes amounts currently due to the Company under IMAX System sale and sales-type lease arrangements, contingent fees owed by theater operators as a result of box office performance, and fees for maintenance services. Accounts receivable also includes amounts due to the Company from movie studios and other content creators principally for digitally remastering films into IMAX formats, as well as for film distribution and post-production services.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

The following tables summarize the activity in the allowance for credit losses related to Accounts Receivable for the three months ended March 31, 2026 and 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| *(In thousands of U.S. Dollars)* | **Theater<br>Operators** | **Studios** | **Other** | **Total** |
| Beginning balance&nbsp;&nbsp;&nbsp;&nbsp; | $12170 | $1310 | $444 | $13924 |
| &nbsp;&nbsp;Current period provision (reversal), net&nbsp;&nbsp;&nbsp;&nbsp; | 138 | 93 | (10) | 221 |
| &nbsp;&nbsp;Write-offs, net of recoveries | (93) | (65) |  | (158) |
| &nbsp;&nbsp;Foreign exchange | (58) | 5 |  | (53) |
| Ending balance | $12157 | $1343 | $434 | $13934 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** |
| *(In thousands of U.S. Dollars)* | **Theater<br>Operators** | **Studios** | **Other** | **Total** |
| Beginning balance&nbsp;&nbsp;&nbsp;&nbsp; | $11678 | $1017 | $583 | $13278 |
| &nbsp;&nbsp;Current period (reversal) provision, net&nbsp;&nbsp;&nbsp;&nbsp; | (116) | 407 | (128) | 163 |
| &nbsp;&nbsp;Write-offs, net of recoveries |  | (188) |  | (188) |
| &nbsp;&nbsp;Foreign exchange | (79) |  |  | (79) |
| Ending balance | $11483 | $1236 | $455 | $13174 |

---

For the three months ended March 31, 2026, the Company's allowance for current expected credit losses related to Accounts Receivable increased by less than $0.1 million. The Company recorded $0.2 million in write-offs in the allowance for credit losses for the three months ended March 31, 2026.

For the three months ended March 31, 2025, the Company's allowance for current expected credit losses related to Accounts Receivable decreased by $0.1 million.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

*Financing Receivables*

Financing receivables are due from theater operators and consist of the Company's net investment in sales-type leases and receivables associated with financed sales of IMAX Systems. As of March 31, 2026 and December 31, 2025, financing receivables consisted of the following:

---

| | | |
|:---|:---|:---|
| | **March 31,** | **December 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Net investment in leases: |  |  |
| &nbsp;&nbsp;Gross minimum payments due under sales-type leases | $32156 | $32628 |
| &nbsp;&nbsp;Unearned finance income | (930) | (1015) |
| &nbsp;&nbsp;&nbsp;&nbsp;Present value of minimum payments due under sales-type leases | 31226 | 31613 |
| &nbsp;&nbsp;Allowance for credit losses | (25) | (458) |
| Net investment in leases | 31201 | 31155 |
| Financed sales receivables: |  |  |
| &nbsp;&nbsp;Gross minimum payments due under financed sales | 125369 | 127099 |
| &nbsp;&nbsp;Unearned finance income | (25150) | (26160) |
| &nbsp;&nbsp;&nbsp;&nbsp;Present value of minimum payments due under financed sales | 100219 | 100939 |
| &nbsp;&nbsp;Allowance for credit losses | (10095) | (10140) |
| Net financed sales receivables | 90124 | 90799 |
| Total financing receivables | $121325 | $121954 |
| Net financed sales receivables due within one year | $31860 | $30660 |
| Net financed sales receivables due after one year | 58264 | 60139 |
| Total financed sales receivables | $90124 | $90799 |

---

As of March 31, 2026 and December 31, 2025, the weighted-average remaining lease term and weighted-average interest rate associated with the Company's sales-type lease arrangements and financed sales receivables, as applicable, were as follows:

---

| | | |
|:---|:---|:---|
| | **March 31,** | **December 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Weighted-average remaining lease term (in years): |  |  |
| &nbsp;&nbsp;Sales-type lease arrangements | 8.5 | 8.6 |
| Weighted-average interest rate |  |  |
| &nbsp;&nbsp;Sales-type lease arrangements | 6.71% | 6.91% |
| &nbsp;&nbsp;Financed sales receivables | 8.71% | 8.68% |

---

The tables below provide information on the Company's net investment in leases by credit quality indicator as of March 31, 2026 and December 31, 2025. The amounts disclosed for each credit quality classification are determined on a theater-by-theater basis as per the origination year of the relationship, and include both billed and unbilled amounts.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *(In thousands of U.S. Dollars)* | **By Origination Year** | **By Origination Year** | **By Origination Year** | **By Origination Year** | **By Origination Year** | **By Origination Year** |  |
| **As of March 31, 2026** | **2026** | **2025** | **2024** | **2023** | **2022** | **Prior** | **Total** |
| Net investment in leases: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Credit quality classification: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;In good standing | $251 | $4803 | $3185 | $2653 | $2711 | $17623 | $31226 |
| &nbsp;&nbsp;&nbsp;&nbsp;Credit Watch |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pre-approved transactions |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Transactions suspended |  |  |  |  |  |  |  |
| Total net investment in leases | $251 | $4803 | $3185 | $2653 | $2711 | $17623 | $31226 |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *(In thousands of U.S. Dollars)* | **By Origination Year** | **By Origination Year** | **By Origination Year** | **By Origination Year** | **By Origination Year** | **By Origination Year** |  |
| **As of December 31, 2025** | **2025** | **2024** | **2023** | **2022** | **2021** | **Prior** | **Total** |
| Net investment in leases: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Credit quality classification: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;In good standing | $4843 | $3277 | $2638 | $2721 | $8562 | $9171 | $31212 |
| &nbsp;&nbsp;&nbsp;&nbsp;Credit Watch |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pre-approved transactions |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Transactions suspended |  |  |  |  |  | 401 | 401 |
| Total net investment in leases | $4843 | $3277 | $2638 | $2721 | $8562 | $9572 | $31613 |

---

The tables below provide information on the Company's financed sales receivables by credit quality indicator as of March 31, 2026 and December 31, 2025. The amounts disclosed for each credit quality classification are determined on a theater-by-theater basis as per the origination year of the relationship, and include both billed and unbilled amounts.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *(In thousands of U.S. Dollars)* | **By Origination Year** | **By Origination Year** | **By Origination Year** | **By Origination Year** | **By Origination Year** | **By Origination Year** |  |
| **As of March 31, 2026** | **2026** | **2025** | **2024** | **2023** | **2022** | **Prior** | **Total** |
| Financed sales receivables: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Credit quality classification: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;In good standing | $2558 | $9773 | $6076 | $6603 | $4285 | $39148 | $68443 |
| &nbsp;&nbsp;&nbsp;&nbsp;Credit Watch |  |  |  |  |  | 853 | 853 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pre-approved transactions |  | 316 | 415 | 1162 | 559 | 12798 | 15250 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transactions suspended |  |  |  |  | 527 | 15146 | 15673 |
| Total financed sales receivables | $2558 | $10089 | $6491 | $7765 | $5371 | $67945 | $100219 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *(In thousands of U.S. Dollars)* | **By Origination Year** | **By Origination Year** | **By Origination Year** | **By Origination Year** | **By Origination Year** | **By Origination Year** |  |
| **As of December 31, 2025** | **2025** | **2024** | **2023** | **2022** | **2021** | **Prior** | **Total** |
| Financed sales receivables: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Credit quality classification: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;In good standing | $11069 | $6537 | $7638 | $4796 | $7642 | $38792 | $76474 |
| &nbsp;&nbsp;&nbsp;&nbsp;Credit Watch |  |  |  |  | 114 | 629 | 743 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pre-approved transactions | 316 | 165 | 369 |  | 428 | 6870 | 8148 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transactions suspended |  |  |  | 527 | 391 | 14656 | 15574 |
| Total financed sales receivables | $11385 | $6702 | $8007 | $5323 | $8575 | $60947 | $100939 |

---

The following tables provide an aging analysis for the Company's net investment in leases and financed sales receivables as of March 31, 2026 and December 31, 2025:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** |
| *(In thousands of U.S. Dollars)* | **Accrued** <br>**and** <br>**Current** | **30-89**<br>**Days** | **90+**<br>**Days** | **Billed** | **Unbilled** | **Recorded Receivable** | **Allowance for Credit Losses** | **Net** |
| Net investment in leases | $235 | $543 | $2758 | $3536 | $27690 | $31226 | $(25) | $31201 |
| Financed sales receivables | 1549 | 1708 | 10384 | 13641 | 86578 | 100219 | (10095) | 90124 |
| Total | $1784 | $2251 | $13142 | $17177 | $114268 | $131445 | $(10120) | $121325 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** |
| *(In thousands of U.S. Dollars)* | **Accrued and Current** | **30-89**<br>**Days** | **90+**<br>**Days** | **Billed** | **Unbilled** | **Recorded Receivable** | **Allowance for Credit Losses** | **Net** |
| Net investment in leases | $670 | $223 | $2278 | $3171 | $28442 | $31613 | $(458) | $31155 |
| Financed sales receivables | 1361 | 887 | 10308 | 12556 | 88383 | 100939 | (10140) | 90799 |
| Total | $2031 | $1110 | $12586 | $15727 | $116825 | $132552 | $(10598) | $121954 |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

The following tables provide information about the Company's net investment in leases and financed sales receivables with billed amounts past due for which it continues to accrue finance income as of March 31, 2026 and December 31, 2025. The amounts disclosed for each credit quality classification are determined on a theater-by-theater basis and include both billed and unbilled amounts.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** |
| *(In thousands of U.S. Dollars)* | **Accrued and Current** | **30-89**<br>**Days** | **90+**<br>**Days** | **Billed** | **Unbilled** | **Allowance for Credit Losses** | **Net** |
| Net investment in leases | $214 | $527 | $2758 | $3499 | $16779 | $(5) | $20273 |
| Financed sales receivables | 620 | 927 | 7467 | 9014 | 24808 | (1303) | 32519 |
| Total | $834 | $1454 | $10225 | $12513 | $41587 | $(1308) | $52792 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** |
| *(In thousands of U.S. Dollars)* | **Accrued and Current** | **30-89**<br>**Days** | **90+**<br>**Days** | **Billed** | **Unbilled** | **Allowance for Credit Losses** | **Net** |
| Net investment in leases | $337 | $165 | $2281 | $2783 | $16129 | $(10) | $18902 |
| Financed sales receivables | 684 | 690 | 7440 | 8814 | 32211 | (1252) | 39773 |
| Total | $1021 | $855 | $9721 | $11597 | $48340 | $(1262) | $58675 |

---

The following table provides information about the Company's net investment in leases and financed sale receivables that were on nonaccrual status as of March 31, 2026 and December 31, 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** |
| *(In thousands of U.S. Dollars)* | **Recorded**<br> **Receivable** | **Allowance for Credit**<br>&nbsp;&nbsp;&nbsp;&nbsp;**Losses** | **Net** | **Recorded**<br> **Receivable** | **Allowance for Credit**<br>&nbsp;&nbsp;&nbsp;&nbsp;**Losses** | **Net** |
| Net investment in leases | $— | $— | $— | $401 | $(401) | $— |
| Net financed sales receivables | 24635 | (9353) | 15282 | 24467 | (9243) | 15224 |
| Total | $24635 | $(9353) | $15282 | $24868 | $(9644) | $15224 |

---

For the three months ended March 31, 2026 and 2025, the Company did not recognize Finance Income related to the net investment in leases on nonaccrual status. For the three months ended March 31, 2026, the Company recognized less than $0.1 million (2025 — less than $0.1 million) in Finance Income related to the financed sales receivables in nonaccrual status.

The following tables summarize the activity in the allowance for credit losses related to the Company's net investment in leases and financed sale receivables for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31, 2026** | **March 31, 2026** |
| *(In thousands of U.S. Dollars)* | **Net Investment <br>in Leases** | **Net Financed<br>Sales Receivables** |
| Beginning balance | $458 | $10140 |
| &nbsp;&nbsp;Current period reversal, net | (434) | (75) |
| &nbsp;&nbsp;Foreign exchange | 1 | 30 |
| Ending balance | $25 | $10095 |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31, 2025** | **March 31, 2025** |
| *(In thousands of U.S. Dollars)* | **Net Investment <br>in Leases** | **Net Financed<br>Sales Receivables** |
| Beginning balance | $664 | $10161 |
| &nbsp;&nbsp;Current period provision (reversal), net | 3 | (199) |
| &nbsp;&nbsp;Foreign exchange |  | (5) |
| Ending balance | $667 | $9957 |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

For the three months ended March 31, 2026, the Company's allowance for current expected credit losses related to its net investment in leases decreased by $0.4 million (2025 — increased by less than $0.1 million), and financed sale receivables decreased by less than $0.1 million (2025 — decreased by $0.2 million).

*Variable Consideration Receivables*

In sale arrangements, variable consideration may become due to the Company from theater operators if certain annual minimum box office receipt thresholds are exceeded. Such variable consideration is recorded as revenue in the period when the sale is recognized and adjusted in future periods based on actual results and changes in estimates. Variable consideration is only recognized to the extent the Company believes there is not a risk of significant revenue reversal.

The following table summarizes the activity in the Allowance for Credit Losses related to Variable Consideration Receivables for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| | **2026** | **2025** |
| <br>*(In thousands of U.S. Dollars)* | **Theater**<br>&nbsp;&nbsp;&nbsp;&nbsp;**Operators** | **Theater**<br>&nbsp;&nbsp;&nbsp;&nbsp;**Operators** |
| Beginning balance | $20 | $116 |
| &nbsp;&nbsp;Current period reversal, net | (14) | (9) |
| Ending balance | $6 | $107 |

---

For the three months ended March 31, 2026, the Company's allowance for current expected credit losses related to Variable Consideration Receivables decreased by less than $0.1 million (2025 — decreased by less than $0.1 million).

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**4. Lease Arrangements**

***IMAX Corporation as a Lessor***

The Company provides IMAX Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system. The customer's rights under the Company's sales-type lease arrangements are described in Note 2 of the Company's audited Consolidated Financial Statements included in its 2025 Form 10-K. Under the Company's sales-type lease arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company's lease portfolio terms are typically non-cancellable for 10 to 20 years with renewal provisions from inception. The Company's sales-type lease arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty generally after the first year of the lease until the end of the lease term. The customer is responsible for obtaining insurance coverage for the IMAX System commencing on the date specified in the arrangement's shipping terms and ending on the date the IMAX System is returned to the Company.

The Company also provides IMAX Systems to customers through JRSAs. Under the traditional form of these arrangements, in exchange for providing the IMAX System under a long-term lease, the Company earns rent based on a percentage of contingent box office receipts and, in some cases, concession revenues, rather than a fixed upfront fee or annual minimum payments.

Under certain other JRSAs, known as hybrid arrangements, the customer is responsible for making fixed upfront payments prior to the delivery and installation of the IMAX System.

Under JRSAs, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company's JRSAs are typically non-cancellable for ten years or longer with renewal provisions. Title to the IMAX System under a JRSA generally does not transfer to the customer. The Company's JRSAs do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the IMAX System commencing on the date specified in the arrangement's shipping terms and ending on the date the IMAX System is returned to the Company.

The following lease payments are expected to be received by the Company for its sales-type leases and JRSAs in each of the remainder of 2026, next four years and thereafter following the March 31, 2026 balance sheet date:

---

| | |
|:---|:---|
| *(In thousands of U.S. Dollars)* | **Sales-Type** <br>**Leases** |
| 2026 (nine months remaining) | $2721 |
| 2027 | 3577 |
| 2028 | 3493 |
| 2029 | 3499 |
| 2030 | 3485 |
| Thereafter | 15381 |
| Total | $32156 |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**5. Inventories**

As of March 31, 2026 and December 31, 2025, Inventories consisted of the following:

---

| | | |
|:---|:---|:---|
| | **March 31,** | **December 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Raw materials | $28680 | $26620 |
| Work-in-process | 1859 | 2280 |
| Finished goods | 5284 | 3605 |
| Total | $35823 | $32505 |

---

As of March 31, 2026, Inventories included balances of $1.6 million (December 31, 2025 — $1.0 million) for which title had passed to the customers, but the criteria for revenue recognition were not met as of the balance sheet date.

During the three months ended March 31, 2026, and 2025, the Company recorded write-downs of less than $0.1 million and $0.1 million, respectively, in Costs and Expenses Applicable to Revenues ― Technology Sales.

 **6. Borrowings**

***Revolving Credit Facility Borrowings, Net***

As of March 31, 2026 and December 31, 2025, Revolving Credit Facility Borrowings, Net included the following:

---

| | | |
|:---|:---|:---|
| | **March 31,** | **December 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Wells Fargo Credit Facility borrowings | $49000 | $37000 |
| Unamortized debt issuance costs | (2298) | (2423) |
| Revolving Credit Facility Borrowings, net | $46702 | $34577 |

---

*Wells Fargo Credit Agreement*

The Company is a party to a Seventh Amended and Restated Credit Agreement, dated as of July 14, 2025 (the "Credit Agreement"), that provides for a credit facility (the "Credit Facility"). The Company's obligations under the Credit Agreement are guaranteed by certain of the Company's subsidiaries (the "Guarantors"), and are secured by first-priority security interests in substantially all of the assets of the Company and the Guarantors.

The Credit Agreement provides for a revolving borrowing capacity of $375.0 million, and contains an uncommitted accordion feature that allows the Company to further increase its borrowing capacity by the greater of $140.0 million or by the Company's EBITDA (as defined in the Credit Agreement) ("Adjusted EBITDA per Credit Facility") for the sum of the four most recently ended fiscal quarters, subject to certain conditions, depending on the mix of revolving loans and/or term loans under the incremental facility and subject to conditions set forth in the Credit Agreement.

The Credit Agreement requires that the Company does not exceed a maximum Senior Secured Net Leverage Ratio (as defined therein) of 3.25:1.00, which may be increased under certain circumstances and is tested on the last day of each fiscal quarter. The Company was in compliance with this requirement as of March 31, 2026 as the Senior Secured Net Leverage Ratio was 0.02:1.00.

Loans under the Credit Facility will bear interest, at the Company's option, at (i) Term SOFR, Eurocurrency Rate or Term CORRA plus a margin ranging from 1.00% to 1.75% per annum or (ii) the U.S. base rate or the Canadian prime rate plus a margin ranging from 0.25% to 1.00% per annum, in each case depending on the Company's total leverage ratio. In no event will Term SOFR, Eurocurrency Rate or Term CORRA be less than 0.00% per annum.

As of March 31, 2026, borrowings under the Credit Facility were $49.0 million (December 31, 2025 — $37.0 million) and bore interest at Term SOFR (as defined in the Credit Agreement), plus a margin of 1.50% per annum (December 31, 2025 — 1.50%) based on the Company's total leverage ratio. The effective interest rate for the three months ended March 31, 2026 was 5.19% (2025 — 6.18%).

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

As of March 31, 2026 and December 31, 2025, the Company had no letters of credit or advance payment guarantees outstanding under the Credit Facility. As of March 31, 2026, the amount available for future borrowings under the Credit Facility was $326.0 million (December 31, 2025 — $338.0 million).

*Foreign Exchange Facility*

Within the Credit Facility, the Company is able to purchase foreign currency forward contracts and/or other swap arrangements. As of March 31, 2026, the net unrealized gain on the Company's outstanding foreign currency forward contracts was less than $0.1 million, representing the amount by which the fair value of these forward contracts exceeded their nominal value (December 31, 2025 — net unrealized gain of $1.0 million). As of March 31, 2026, the notional value of the Company's outstanding foreign currency forward contracts was $38.5 million (December 31, 2025 — $48.4 million).

*Bank of China Facility*

As of March 31, 2026, and December 31, 2025, there were no borrowings outstanding under the Bank of China Facility (as defined and described in Note 13 to the Company's audited Consolidated Financial Statements in its 2025 Form 10-K) and outstanding letters of guarantee were RMB 0.8 million ($0.1 million).

As of March 31, 2026, the amount available for future borrowings under the Bank of China Facility was RMB 190.0 million ($27.5 million) and the amount available for letters of guarantee was RMB 9.2 million ($1.3 million). The amount available for future borrowings under the Bank of China Facility is not subject to a standby fee. The effective interest rate for the three months ended March 31, 2026 was 0% (2025 — 0%). There were no amounts drawn under the Bank of China Facility during the three months ended March 31, 2026. The Bank of China Facility has been renewed to April 15, 2027.

*HSBC China Facility*

As of March 31, 2026, and December 31, 2025, no borrowings were outstanding under the HSBC China Facility (as defined and described in Note 13 to the Company's audited Consolidated Financial Statements in its 2025 Form 10-K). As of March 31, 2026, and December 31, 2025 the amount available for future borrowings under the HSBC China Facility was RMB 200.0 million ($28.9 million). The effective interest rate for the three months ended March 31, 2026 was 0% (December 2025 — 0%).

*NBC Facility*

The NBC Facility (as defined and described in Note 13 to the Company's audited Consolidated Financial Statements in its 2025 Form 10-K) has been renewed to October 8, 2026. The Company did not have any letters of credit or advance payment guarantees outstanding as of March 31, 2026 and December 31, 2025 under the NBC Facility.

***Convertible Notes and Other Borrowings, Net***

As of March 31, 2026 and December 31, 2025, Convertible Notes and Other Borrowings, Net included the following:

---

| | | |
|:---|:---|:---|
| | **March 31,** | **December 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Convertible Notes | $250526 | $250743 |
| Unamortized discounts and debt issuance costs | (7218) | (7636) |
| Convertible Notes, net | 243308 | 243107 |
| Federal Economic Development Loan | 879 | 1027 |
| Unaccreted interest benefit | (59) | (100) |
| Federal Economic Development Loan, net | 820 | 927 |
| Convertible Notes and Other Borrowings, net | $244128 | $244034 |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

*2026 Convertible Notes*

On March 19, 2021, the Company issued $230.0 million of 0.500% Convertible Senior Notes due 2026 (the "2026 Convertible Notes"). In connection with the pricing of the 2026 Convertible Notes, the Company entered into privately negotiated capped call transactions (the "2026 Capped Call Transactions") with certain financial institutions to reduce potential dilution in connection with the redemption of the 2026 Convertible Notes.

On November 6, 2025, the Company completed the repurchase of $229.3 million (or 99.7%) of the outstanding principal amount of the 2026 Convertible Notes in separate, privately negotiated repurchase transactions with a limited number of holders. During the three months ended March 31, 2026, certain holders of the remaining outstanding 2026 Convertible Notes elected to convert 217 notes ($0.2 million) of the outstanding principal. As a result of this election, the Company recorded a loss on debt extinguishment of $0.1 million in Interest Expense in the Condensed Consolidated Statement of Operations. As of March 31, 2026, the Company recorded a $0.3 million liability in Accrued and other liabilities in the Condensed Consolidated Balance Sheet. The liability for the converted bonds was settled on April 1, 2026, along with the remaining unconverted and outstanding 2026 Convertible Notes. Concurrently with this April 1, 2026 transaction, the Company terminated the remaining portion of the associated 2026 capped call transactions.

*2030 Convertible Notes*

On November 6, 2025, the Company issued $250.0 million of 0.750% Convertible Senior Notes due 2030 (the "2030 Convertible Notes") in a private placement conducted pursuant to Rule 144A under the Securities Act of 1933, as amended. The net proceeds from the issuance of the 2030 Convertible Notes were $243.1 million, after deducting the initial purchasers' discounts and commissions, and were used to repurchase $229.3 million of the outstanding principal amount of the 2026 Convertible Notes.

The 2030 Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 0.750% per annum on the principal of $250.0 million, payable semi-annually in arrears on May 15 and November 15 of each year. The 2030 Convertible Notes will mature on November 15, 2030, unless they are redeemed or repurchased by the Company or converted on an earlier date.

The Company continues to record the Convertible Notes entirely as a liability on the Condensed Consolidated Balance Sheets, net of initial purchasers' discounts and commissions and other debt issuance costs, with interest expense reflecting the cash coupon plus the amortization of the discounts and capitalized costs.

*Federal Economic Development Loan* 

As of March 31, 2026, the Federal Economic Development Loan (as defined and described in Note 13 to the Company's audited Consolidated Financial Statements in its 2025 Form 10-K) had a carrying value of $0.8 million, net of unaccreted interest benefit and is recorded within Convertible Notes and Other Borrowings, Net on the Company's Condensed Consolidated Balance Sheets.

**7. Commitments, Contingencies and Guarantees**

***Commitments***

In the ordinary course of its business, the Company enters into contractual agreements with third parties that include non-cancelable payment obligations, for which it is liable in future periods. These arrangements can include terms binding the Company to minimum payments and/or penalties if it terminates the agreement for any reason other than an event of default as described by the agreement.

***Contingencies and guarantees***

The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. Management is required to assess the likelihood of any adverse judgments or outcomes related to these legal contingencies, as well as potential ranges of probable or reasonably possible losses. The Company records a provision for a liability when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The determination of the amount of any liability recorded or disclosed is reviewed at least quarterly based on a careful analysis of each individual exposure with, in some cases, the assistance of outside legal counsel, taking into account the impact of negotiations, settlements, rulings, and other pertinent information related to the case. The amount of liabilities recorded or disclosed for these contingencies may change in the future due to changes in management's judgments resulting from new developments or changes in settlement strategy. Any resulting adjustment to the liabilities recorded by the Company could have a material adverse effect on its results of operations, cash flows, and financial position in the period or periods in which such changes in judgment occur. The Company believes it has adequate provisions for any such matters. The Company expenses legal costs relating to its lawsuits, claims, and proceedings as incurred.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

In January 2004, the Company and IMAX Theatre Services Ltd., a subsidiary of the Company, commenced an arbitration seeking damages before the International Court of Arbitration of the International Chamber of Commerce (the "ICC") with respect to the breach by Electronic Media Limited ("EML") of its December 2000 agreement with the Company. In June 2004, the Company commenced a related arbitration before the ICC against EML's affiliate, E-City Entertainment (I) PVT Limited ("E-City"). On March 27, 2008, the arbitration panel issued a final award in favor of the Company in the amount of $11.3 million, as well as an additional $2,512 each day in interest from October 1, 2007 until the date the award is paid. In July 2008, E-City commenced a proceeding in Mumbai, India seeking to prevent recognition of the ICC award in India. On March 10, 2017, the Supreme Court of India dismissed E-City's petition. On March 29, 2017, the Company filed an Execution Application in the Bombay High Court seeking to enforce the ICC award against E-City and several related parties. On December 30, 2025, the Commercial Appellate Division of the Bombay High Court rejected E-City's objections to enforcement of the arbitration award and recognized the award as a decree of the Court. The E-City parties appealed this decision to the Supreme Court of India. The Company fully intends to continue pursuing its rights and seeking to enforce the arbitration award. No amounts have been recognized in connection with this matter.

***Financial Guarantees***

Certain subsidiaries of the Company have provided significant financial guarantees to third parties under the Credit Agreement.

***Director and Officer Indemnifications***

The Company's by-laws contain an indemnification of its directors/officers, former directors/officers, and persons who have acted at its request to be a director/officer of an entity in which the Company is a shareholder or creditor, to indemnify them, to the extent permitted by the *Canada Business Corporations Act*, against expenses (including legal fees), judgments, fines and any amounts actually and reasonably incurred by them in connection with any action, suit or proceeding in which the directors and/or officers are sued as a result of their service, if they acted honestly and in good faith with a view to the best interests of the Company. In addition, the Company has entered into indemnification agreements with each of its directors in order to effectuate the foregoing. The nature of the indemnification prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to counterparties. The Company has purchased directors' and officers' liability insurance. No amount has been accrued on the Company's Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025, with respect to this indemnity.

***Other Indemnification Agreements***

In the normal course of its operations, the Company provides indemnifications to counterparties in transactions such as: IMAX System lease and sale agreements and the supervision of installation or servicing of IMAX Systems; film production, exhibition and distribution agreements; real property lease agreements; and employment agreements. These indemnification agreements require the Company to compensate the counterparties for costs incurred as a result of litigation claims that may be suffered by the counterparty as a consequence of the transaction or the Company's breach or non-performance under these agreements. While the terms of these indemnification agreements vary based upon the contract, they normally extend for the life of the agreements. A small number of agreements do not provide for any limit on the maximum potential amount of indemnification; however, virtually all of the IMAX System lease and sale agreements limit such maximum potential liability to the purchase price of the system. The fact that the maximum potential amount of indemnification required by the Company is not specified in some cases prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to counterparties. Historically, the Company has not made any significant payments under such indemnifications and no amounts have been accrued in the Condensed Consolidated Financial Statements with respect to the contingent aspect of these indemnities.

**8. Condensed Consolidated Statements of Operations – Supplemental Information**

***Selling Expenses***

The following table summarizes the Company's selling expenses, including sales commissions and marketing and other, which are recognized within Costs and Expenses Applicable to Revenues in the Condensed Consolidated Statements of Operations, for the three months ended March 31, 2026 and 2025:

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| *(In thousands of U.S. Dollars)* | **Sales <br>Commissions** | **Marketing <br>and Other** | **Sales** <br>**Commissions** | **Marketing** <br>**and Other** |
| Technology sales<sup>(1)</sup> | $191 | $(69) | $180 | $55 |
| Image enhancement and maintenance services<sup>(2)</sup> |  | 5474 |  | 2435 |
| Technology rentals<sup>(3)</sup> | 121 | 519 | 66 | 331 |
| Total | $312 | $5924 | $246 | $2821 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Sales commissions paid prior to the recognition of the related revenue are deferred and recognized upon the client acceptance of the IMAX System. Direct advertising and marketing costs for each IMAX System are expensed as incurred and may be reversed when the contractual obligation ceases to exist.*<br>*(2)Film exploitation costs, including advertising and marketing costs, are expensed as incurred.*<br>*(3)Sales commissions related to joint revenue sharing arrangements accounted for as operating leases are recognized in the month they are earned by the salesperson, which is typically the month in which the IMAX System is installed, and are subject to subsequent performance-based adjustments. Direct advertising and marketing costs for each IMAX System are expensed as incurred and may be reversed when the contractual obligation cease to exist.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Sales commissions paid prior to the recognition of the related revenue are deferred and recognized upon the client acceptance of the IMAX System. Direct advertising and marketing costs for each IMAX System are expensed as incurred and may be reversed when the contractual obligation ceases to exist.*<br>*(2)Film exploitation costs, including advertising and marketing costs, are expensed as incurred.*<br>*(3)Sales commissions related to joint revenue sharing arrangements accounted for as operating leases are recognized in the month they are earned by the salesperson, which is typically the month in which the IMAX System is installed, and are subject to subsequent performance-based adjustments. Direct advertising and marketing costs for each IMAX System are expensed as incurred and may be reversed when the contractual obligation cease to exist.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Sales commissions paid prior to the recognition of the related revenue are deferred and recognized upon the client acceptance of the IMAX System. Direct advertising and marketing costs for each IMAX System are expensed as incurred and may be reversed when the contractual obligation ceases to exist.*<br>*(2)Film exploitation costs, including advertising and marketing costs, are expensed as incurred.*<br>*(3)Sales commissions related to joint revenue sharing arrangements accounted for as operating leases are recognized in the month they are earned by the salesperson, which is typically the month in which the IMAX System is installed, and are subject to subsequent performance-based adjustments. Direct advertising and marketing costs for each IMAX System are expensed as incurred and may be reversed when the contractual obligation cease to exist.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Sales commissions paid prior to the recognition of the related revenue are deferred and recognized upon the client acceptance of the IMAX System. Direct advertising and marketing costs for each IMAX System are expensed as incurred and may be reversed when the contractual obligation ceases to exist.*<br>*(2)Film exploitation costs, including advertising and marketing costs, are expensed as incurred.*<br>*(3)Sales commissions related to joint revenue sharing arrangements accounted for as operating leases are recognized in the month they are earned by the salesperson, which is typically the month in which the IMAX System is installed, and are subject to subsequent performance-based adjustments. Direct advertising and marketing costs for each IMAX System are expensed as incurred and may be reversed when the contractual obligation cease to exist.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Sales commissions paid prior to the recognition of the related revenue are deferred and recognized upon the client acceptance of the IMAX System. Direct advertising and marketing costs for each IMAX System are expensed as incurred and may be reversed when the contractual obligation ceases to exist.*<br>*(2)Film exploitation costs, including advertising and marketing costs, are expensed as incurred.*<br>*(3)Sales commissions related to joint revenue sharing arrangements accounted for as operating leases are recognized in the month they are earned by the salesperson, which is typically the month in which the IMAX System is installed, and are subject to subsequent performance-based adjustments. Direct advertising and marketing costs for each IMAX System are expensed as incurred and may be reversed when the contractual obligation cease to exist.* |

---

Included in Selling, General and Administrative Expenses for the three months ended March 31, 2026 is a foreign currency net loss of $0.6 million (2025 — net loss of $0.4 million), resulting from changes in exchange rates related to foreign currency denominated monetary assets and liabilities. (Refer to "Financial Instruments — *Foreign Exchange Risk Management*" in Note 15 for additional information.)

***Collaborative Arrangements***

*Joint Revenue Sharing Arrangements*

The accounting policy for the Company's JRSAs is disclosed in Note 2 of the Company's audited Consolidated Financial Statements in its 2025 Form 10-K.

Revenue attributable to transactions arising between the Company and its customers under JRSAs is recorded within Revenues — Technology Sales (for hybrid JRSAs) and Revenues — Technology Rentals (for traditional JRSAs). For the three months ended March 31, 2026, such revenues totaled $16.4 million (2025 — $19.2 million).

*IMAX Film Remastering and Distribution*

The Company earns revenue through the digital remastering of films and other content into IMAX formats for distribution to the IMAX network ("IMAX Film Remastering"). The accounting policy for IMAX Film Remastering and distribution arrangements is disclosed in Note 2 of the Company's audited Consolidated Financial Statements in its 2025 Form 10-K.

Revenue attributable to transactions arising between the Company and its customers under IMAX Film Remastering and distribution arrangements is included in Revenues – Image Enhancement and Maintenance Services. For the three months ended March 31, 2026, such revenues totaled $29.2 million (2025 — $31.8 million). (Refer to "Revenue from Contracts with Customers — *Disaggregated Information About Revenue*" in Note 12 for a disaggregated presentation of the Company's revenues.)

*Co-Produced Film Arrangements*

The accounting policies relating to co-produced film arrangements are disclosed in Notes 2 and 3 of the Company's audited Consolidated Financial Statements in its 2025 Form 10-K.

As of March 31, 2026, the Company is party to one co-produced film arrangement, which represented the VIE total assets balance of $1.8 million and liabilities balance of $0.4 million, and four other co-produced film arrangements, the terms of which are similar.

For the three months ended March 31, 2026, an expense of $0.1 million (2025 — $0.1 million) attributable to transactions between the Company and other parties involved in the production of the films has been included in Costs and Expenses Applicable to Revenues ― Image Enhancement and Maintenance Services.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**9. Condensed Consolidated Statements of Cash Flows – Supplemental Information**

***Changes in other operating assets and liabilities***

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Decrease (increase) in: |  |  |
| &nbsp;&nbsp;Financing receivables | $1032 | $208 |
| &nbsp;&nbsp;Prepaid expenses | (1783) | (917) |
| &nbsp;&nbsp;Variable consideration receivables | 793 | (413) |
| &nbsp;&nbsp;Other assets, excluding lease incentives provided to exhibitor customers | (59) | 1869 |
| (Decrease) increase in: |  |  |
| &nbsp;&nbsp;Accounts payable | (2194) | 5148 |
| &nbsp;&nbsp;Accrued and other liabilities | (8635) | (7081) |
| Total | $(10846) | $(1186) |

---

***Depreciation and amortization***

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Film assets | $3842 | $4339 |
| Property, plant and equipment: |  |  |
| &nbsp;&nbsp;Equipment supporting JRSAs | 5969 | 5662 |
| &nbsp;&nbsp;Other property, plant and equipment | 2316 | 2216 |
| Other intangible assets | 2353 | 2066 |
| Other assets | 756 | 630 |
| Total | $15236 | $14913 |

---

***Write-downs***

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Inventories | 50 | $103 |
| Property, plant and equipment: |  |  |
| &nbsp;&nbsp;Equipment supporting JRSAs | 7 | 88 |
| &nbsp;&nbsp;Other property, plant and equipment |  | 2 |
| Total | $57 | $193 |

---

***Significant non-cash investing activities***

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Net increase in accruals related to: |  |  |
| &nbsp;&nbsp;Investment in equipment supporting JRSAs | $551 | $1134 |
| &nbsp;&nbsp;Acquisition of other intangible assets | (71) | (6) |
| &nbsp;&nbsp;Purchases of property, plant and equipment | 28 |  |
| Net amount | $508 | $1128 |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**10. Income Taxes** 

For the three months ended March 31, 2026, the Company recorded an income tax expense of $2.4 million (2025 — $7.3 million). The Company's effective tax rate of 28.5% for the three months ended March 31, 2026 reflects the geographic allocation of income earned in taxing jurisdictions and reflects an increase in the valuation allowance and withholding taxes, offset by a tax benefit related to share-based compensation. The Company's effective tax rate of 47.2% for the three months ended March 31, 2025 reflects the geographic allocation of income earned in taxing jurisdictions and also reflects an increase in the valuation allowance, withholding taxes and a tax benefit related to share-based compensation.

As of March 31, 2026, the Company's Condensed Consolidated Balance Sheets included net deferred income tax assets of $12.7 million (December 31, 2025 — $12.6 million). Realization of net deferred tax assets is dependent upon generation of sufficient taxable income in future years to obtain benefit from the reversal of temporary differences, net operating loss carryforwards and tax credit carryforwards. The amount of net deferred tax assets considered realizable is subject to adjustment in future periods if estimates of future taxable income change.

As of March 31, 2026, the Company's Condensed Consolidated Balance Sheets also included deferred tax liabilities of $12.5 million (December 31, 2025 — $12.5 million) primarily related to foreign withholding taxes associated with the remaining balance of non-repatriated historical earnings that will not be indefinitely reinvested outside of Canada.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**11. Capital Stock and Reserves**

***Share-Based Compensation***

For the three months ended March 31, 2026, share-based compensation expense totaled $5.7 million (2025 — $5.2 million) and is reflected in the following accounts in the Condensed Consolidated Statements of Operations:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Costs and expenses applicable to revenues | $299 | $291 |
| Selling, general and administrative expenses | 5252 | 4720 |
| Research and development | 174 | 194 |
| Total | $5725 | $5205 |

---

The following table summarizes the Company's share-based compensation expense by each award type:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Restricted Share Units | $2889 | $2867 |
| Performance Stock Units | 2335 | 1932 |
| IMAX China Long Term Incentive Plan Restricted Share Units | 334 | 313 |
| IMAX China Long Term Incentive Plan Performance Stock Units | 167 | 93 |
|  | $5725 | $5205 |

---

For the three months ended March 31, 2026, the Company's share-based compensation expense included restricted share units to non-employees of $nil that were granted and have not yet vested (2025 — less than $0.1 million, which vested immediately upon granting).

*Stock Option Summary*

The following table summarizes the activity under the Company's Stock Option Plan ("SOP") for the three months ended March 31, 2026 and 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Number of Shares** | **Number of Shares** | **Weighted Average Exercise <br>Price Per Share** | **Weighted Average Exercise <br>Price Per Share** |
| | **2026** | **2025** | **2026** | **2025** |
| Stock options outstanding, beginning of period | 1818698 | 2469238 | $25.82 | $26.27 |
| &nbsp;&nbsp;Exercised | (121223) | (44031) | 31.40 | 21.54 |
| &nbsp;&nbsp;Expired |  | (470582) |  | 29.53 |
| Stock options outstanding, end of period | 1697475 | 1954625 | 25.42 | 25.59 |
| Stock options exercisable, end of period | 1697475 | 1954625 | 25.42 | 25.59 |

---

Stock options are no longer granted under the SOP.

*IMAX LTIP Restricted Share Units ("RSU") Summary*

The following table summarizes the activity in respect of RSUs issued under the IMAX Corporation Second Amended and Restated Long-Term Incentive Plan (as may be amended, "IMAX LTIP") for the three months ended March 31, 2026 and 2025:

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Number of Shares** | **Number of Shares** | **Weighted Average Grant Date <br>Fair Value Per Share** | **Weighted Average Grant Date <br>Fair Value Per Share** |
| | **2026** | **2025** | **2026** | **2025** |
| RSUs outstanding, beginning of period | 1244670 | 1465977 | $20.10 | $17.16 |
| &nbsp;&nbsp;Granted | 348671 | 497692 | 36.68 | 25.02 |
| &nbsp;&nbsp;Vested and settled | (650852) | (667768) | 18.96 | 17.58 |
| &nbsp;&nbsp;Forfeited | (4030) | (6274) | 25.12 | 17.94 |
| RSUs outstanding, end of period | 938459 | 1289627 | 27.02 | 19.98 |

---

*IMAX LTIP Performance Stock Units ("PSU") Summary*

The Company grants two types of PSU award, one which vests based on a combination of employee service and the achievement of certain Adjusted EBITDA targets and one which vests based on a combination of employee service and the achievement of total shareholder return ("TSR") targets. The achievement of these targets is assessed over a three-year performance period, with vesting ranging from 0% to 200% of the initial Adjusted EBITDA PSU award or 200% of the initial TSR PSU award, depending upon actual performance.

For the 2026 grants, the grant date fair value for Adjusted EBITDA PSUs is determined using the volume-weighted average price of the Company's common shares on the New York Stock Exchange for the sixty calendar days prior to the date of grant. The grant date fair value for TSR PSUs is determined using a Monte Carlo Model, influenced by share price and various assumptions, such as market conditions and expected share price volatility over the term of the awards.

The compensation expense attributable for each type of PSU is recognized on a straight-line basis over the requisite service period. If, as a result of management's assessment, it is projected that a greater or lesser number of PSUs will vest than previously anticipated, a life-to-date adjustment to increase or decrease compensation expense is recorded in the period that such determination is made. The expense recognized in the three months ended March 31, 2026 and 2025 includes adjustments reflecting management's estimate of the number of Adjusted EBITDA PSUs expected to vest.

The following table summarizes the activity in respect of PSUs issued under the IMAX LTIP for the three months ended March 31, 2026 and 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Number of Awards** | **Number of Awards** | **Weighted Average Grant Date <br>Fair Value Per Share** | **Weighted Average Grant Date <br>Fair Value Per Share** | **Weighted Average Grant Date <br>Fair Value Per Share** | **Weighted Average Grant Date <br>Fair Value Per Share** |
| | **2026** | **2025** | **2026** | **2026** | **2025** | **2025** |
| PSUs outstanding, beginning of period | 1140515 | 1097634 | $| 20.12 | $| 17.99 |
| &nbsp;&nbsp;Granted<sup>(1)(2)</sup> | 491275 | 551084 | 29.38 | 29.38 | 24.17 | 24.17 |
| &nbsp;&nbsp;Vested and settled<sup>(1)(2)</sup> | (605004) | (463212) | 17.61 | 17.61 | 19.88 | 19.88 |
| &nbsp;&nbsp;Forfeited | (1861) | (3043) | 20.15 | 20.15 | 18.48 | 18.48 |
| PSUs outstanding, end of period | 1024925 | 1182463 | 26.04 | 26.04 | 20.13 | 20.13 |
| <br>*(1) For the three months ended March 31, 2026, the balance of shares granted includes 199,473 (2025 - 159,376) additional shares, at a weighted average grant date fair value per share of $16.98 (2025 - $19.18), as PSUs granted in 2023 with Adjusted EBITDA targets vested at 175% (2025 - 175%) on account of full achievement of the targets.* <br>*(2) For the three months ended March 31, 2026, the balance of shares granted includes 46,510 (2025 - 17,375) additional shares, at a weighted average grant date fair value per share of $19.73 (2025 - $22.72), as PSUs granted in 2023 with TSR targets vested at 150% on account of full achievement of the targets (2025 - 123.5% based on actual performance versus the targets).* | <br>*(1) For the three months ended March 31, 2026, the balance of shares granted includes 199,473 (2025 - 159,376) additional shares, at a weighted average grant date fair value per share of $16.98 (2025 - $19.18), as PSUs granted in 2023 with Adjusted EBITDA targets vested at 175% (2025 - 175%) on account of full achievement of the targets.* <br>*(2) For the three months ended March 31, 2026, the balance of shares granted includes 46,510 (2025 - 17,375) additional shares, at a weighted average grant date fair value per share of $19.73 (2025 - $22.72), as PSUs granted in 2023 with TSR targets vested at 150% on account of full achievement of the targets (2025 - 123.5% based on actual performance versus the targets).* | <br>*(1) For the three months ended March 31, 2026, the balance of shares granted includes 199,473 (2025 - 159,376) additional shares, at a weighted average grant date fair value per share of $16.98 (2025 - $19.18), as PSUs granted in 2023 with Adjusted EBITDA targets vested at 175% (2025 - 175%) on account of full achievement of the targets.* <br>*(2) For the three months ended March 31, 2026, the balance of shares granted includes 46,510 (2025 - 17,375) additional shares, at a weighted average grant date fair value per share of $19.73 (2025 - $22.72), as PSUs granted in 2023 with TSR targets vested at 150% on account of full achievement of the targets (2025 - 123.5% based on actual performance versus the targets).* | <br>*(1) For the three months ended March 31, 2026, the balance of shares granted includes 199,473 (2025 - 159,376) additional shares, at a weighted average grant date fair value per share of $16.98 (2025 - $19.18), as PSUs granted in 2023 with Adjusted EBITDA targets vested at 175% (2025 - 175%) on account of full achievement of the targets.* <br>*(2) For the three months ended March 31, 2026, the balance of shares granted includes 46,510 (2025 - 17,375) additional shares, at a weighted average grant date fair value per share of $19.73 (2025 - $22.72), as PSUs granted in 2023 with TSR targets vested at 150% on account of full achievement of the targets (2025 - 123.5% based on actual performance versus the targets).* | <br>*(1) For the three months ended March 31, 2026, the balance of shares granted includes 199,473 (2025 - 159,376) additional shares, at a weighted average grant date fair value per share of $16.98 (2025 - $19.18), as PSUs granted in 2023 with Adjusted EBITDA targets vested at 175% (2025 - 175%) on account of full achievement of the targets.* <br>*(2) For the three months ended March 31, 2026, the balance of shares granted includes 46,510 (2025 - 17,375) additional shares, at a weighted average grant date fair value per share of $19.73 (2025 - $22.72), as PSUs granted in 2023 with TSR targets vested at 150% on account of full achievement of the targets (2025 - 123.5% based on actual performance versus the targets).* | <br>*(1) For the three months ended March 31, 2026, the balance of shares granted includes 199,473 (2025 - 159,376) additional shares, at a weighted average grant date fair value per share of $16.98 (2025 - $19.18), as PSUs granted in 2023 with Adjusted EBITDA targets vested at 175% (2025 - 175%) on account of full achievement of the targets.* <br>*(2) For the three months ended March 31, 2026, the balance of shares granted includes 46,510 (2025 - 17,375) additional shares, at a weighted average grant date fair value per share of $19.73 (2025 - $22.72), as PSUs granted in 2023 with TSR targets vested at 150% on account of full achievement of the targets (2025 - 123.5% based on actual performance versus the targets).* | <br>*(1) For the three months ended March 31, 2026, the balance of shares granted includes 199,473 (2025 - 159,376) additional shares, at a weighted average grant date fair value per share of $16.98 (2025 - $19.18), as PSUs granted in 2023 with Adjusted EBITDA targets vested at 175% (2025 - 175%) on account of full achievement of the targets.* <br>*(2) For the three months ended March 31, 2026, the balance of shares granted includes 46,510 (2025 - 17,375) additional shares, at a weighted average grant date fair value per share of $19.73 (2025 - $22.72), as PSUs granted in 2023 with TSR targets vested at 150% on account of full achievement of the targets (2025 - 123.5% based on actual performance versus the targets).* |

---

As of March 31, 2026, the maximum number of common shares that may be issued with respect to PSUs outstanding was 1,797,285, assuming full achievement of the Adjusted EBITDA and TSR targets.

***Issuer Purchases of Equity Securities***

On June 12, 2017, the Company announced that its Board of Directors approved a $200.0 million share repurchase program for its common shares that would have expired on June 30, 2020, which was subsequently extended through June 30, 2026 and increased to a total share repurchase authority of $500.0 million under the current share repurchase program. As of March 31, 2026, the Company had $250.7 million available under the program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant to a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

During the three months ended March 31, 2026, and 2025, the Company did not repurchase any common shares. During the three months ended March 31, 2026 and 2025, there were no shares purchased in the administration of employee share based plans.

As of March 31, 2026 and December 31, 2025, the IMAX LTIP trustee did not hold any shares. Any shares held with the trustee are recorded at cost and are reported as a reduction against Capital Stock on the Company's Condensed Consolidated Balance Sheets.

In 2024, IMAX China's shareholders granted its Board of Directors a general mandate authorizing IMAX China's Board of Directors, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10% of the total number of issued shares as of June 7, 2024 (34,000,845 shares). This program expired on the date of the 2025 Annual General Meeting of IMAX China on June 12, 2025. During IMAX China's 2025 Annual General Meeting, shareholders granted its Board of Directors a general mandate, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10% of the total number of issued shares as of June 12, 2025 (33,919,122 shares). This program will be valid until the 2026 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time.

During the three months ended March 31, 2026 and 2025, IMAX China did not repurchase any of its common shares.

***Basic and Diluted Weighted Average Shares Outstanding***

The following table reconciles the denominator of the basic and diluted weighted average share computations:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| *(In thousands)* | **2026** | **2025** |
| Issued and outstanding, beginning of period | 53922 | 52946 |
| Weighted average number of shares issued, net | 203 | 199 |
| Weighted average number of shares outstanding - basic | 54125 | 53145 |
| Weighted average effect of potential common shares, if dilutive | 2267 | 1824 |
| Weighted average number of shares outstanding - diluted | 56392 | 54969 |

---

For the three months ended March 31, 2026, the calculation of diluted weighted average shares outstanding excludes 72,493 shares (2025 — 971,374 shares) that are issuable upon the vesting or exercise of share-based compensation including: (i) nil RSUs (2025 — nil RSUs), (ii) 72,493 PSUs (2025 — 128,333 PSUs) and (iii) nil stock options (2025 — 843,041 stock options), as the effect would be anti-dilutive.

The calculation of diluted weighted average shares outstanding for the three months ended March 31, 2026 and 2025 also excludes any shares potentially issuable upon the conversion of the Convertible Notes as the average market price of the Company's common shares during the period of time they were outstanding was less than the conversion price of the Convertible Notes.

***Statutory Surplus Reserve***

Pursuant to the corporate law of the People's Republic of China ("PRC"), entities registered in the PRC are required to maintain certain statutory reserves, which are appropriated from after-tax profits (after offsetting accumulated losses from prior years), as reported in their respective statutory financial statements, before the declaration or payment of dividends to equity holders. All statutory reserves are created for specific purposes.

The statutory surplus reserve of RMB 37.7 million ($5.8 million) has reached 50% of the Company's PRC subsidiaries' registered capital, and as such, no further contributions to the reserve are required.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**12. Revenue from Contracts with Customers**

***Disaggregated Information About Revenue***

The following tables summarize the Company's Revenues by reportable segment and revenue stream type for the three months ended March 31, 2026 and 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
| *(In thousands of U.S. Dollars)* | **Technology Sales** | **Image Enhancement and Maintenance Services** | **Technology Rentals** | **Finance Income** | **Total** |
| Content Solutions Segment: |  |  |  |  |  |
| &nbsp;&nbsp;Film Remastering and Distribution | $— | $29227 | $— | $— | $29227 |
| &nbsp;&nbsp;Other Content Solutions |  | 2094 | 49 |  | 2143 |
|  |  | 31321 | 49 |  | 31370 |
| Technology Products and Services Segment: |  |  |  |  |  |
| &nbsp;&nbsp;System Sales | 12417 |  |  |  | 12417 |
| &nbsp;&nbsp;System Rentals |  |  | 16575 |  | 16575 |
| &nbsp;&nbsp;Maintenance |  | 16589 |  |  | 16589 |
| &nbsp;&nbsp;Finance Income |  |  |  | 2757 | 2757 |
|  | 12417 | 16589 | 16575 | 2757 | 48338 |
| &nbsp;&nbsp;Sub-total for reportable segments | 12417 | 47910 | 16624 | 2757 | 79708 |
| All Other | 997 | 674 |  |  | 1671 |
| Total | $13414 | $48584 | $16624 | $2757 | $81379 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| *(In thousands of U.S. Dollars)* | **Technology Sales** | **Image Enhancement and Maintenance Services** | **Technology Rentals** | **Finance Income** | **Total** |
| Content Solutions Segment |  |  |  |  |  |
| &nbsp;&nbsp;Film Remastering and Distribution | $— | $32157 | $— | $— | $32157 |
| &nbsp;&nbsp;Other Content Solutions |  | 1917 | 175 |  | 2092 |
|  |  | 34074 | 175 |  | 34249 |
| Technology Products and Services Segment |  |  |  |  |  |
| &nbsp;&nbsp;System Sales | 12720 |  |  |  | 12720 |
| &nbsp;&nbsp;System Rentals |  |  | 19136 |  | 19136 |
| &nbsp;&nbsp;Maintenance |  | 15658 |  |  | 15658 |
| &nbsp;&nbsp;Finance Income |  |  |  | 3079 | 3079 |
|  | 12720 | 15658 | 19136 | 3079 | 50593 |
| &nbsp;&nbsp;Sub-total for reportable segments | 12720 | 49732 | 19311 | 3079 | 84842 |
| All Other | 804 | 1021 |  |  | 1825 |
| Total | $13524 | $50753 | $19311 | $3079 | $86667 |

---

For the three months ended March 31, 2026, revenues earned from Technology Sales included variable consideration of $4.3 million (2025 — $3.2 million).

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

***Deferred Revenue***

IMAX System sale and lease arrangements include a requirement for the Company to provide maintenance services over the life of the arrangement, some of which maintenance services are subject to a consumer price index adjustment each year. In circumstances where customers prepay the entire term's maintenance fee based on the original arrangement, additional payments are due to the Company for the years after its extended warranty and maintenance obligations expire. Payments, upon renewal each year, are either prepaid or made in arrears and can vary in frequency from monthly to annually. As of March 31, 2026, $21.4 million of consideration has been deferred in relation to outstanding maintenance services to be provided on existing maintenance contracts (December 31, 2025 — $28.3 million).

During the three months ended March 31, 2026, $8.8 million of revenue was recognized from the $50.4 million balance of deferred revenue as of December 31, 2025. During the three months ended March 31, 2025, $9.0 million of revenue was recognized from the $52.7 million balance of deferred revenue as of December 31, 2024.

**13. Segment Reporting**

The Company's Chief Executive Officer ("CEO") is its Chief Operating Decision Maker ("CODM"), as such term is defined under U.S. GAAP. The CODM assesses segment performance based on segment revenues and segment gross margins. Selling, general and administrative expenses, research and development costs, the amortization of intangible assets, provision for (reversal of) current expected credit losses, certain write-downs, interest income, interest expense, and income tax (expense) benefit are not allocated to the Company's segments.

The accounting policies of the reportable segments are the same as those described in Note 2 - Summary of Significant Accounting Policies of the 2025 Form 10-K. Intercompany profit or loss is not included in the evaluation of performance and allocation of resources.

The following table presents the Company's revenue and gross margin by reportable segment for the three months ended March 31, 2026 and 2025:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Revenue**<sup>(1)</sup> | **Revenue**<sup>(1)</sup> | **Revenue**<sup>(1)</sup> | **Revenue**<sup>(1)</sup> | **Gross Margin** | **Gross Margin** | **Gross Margin** | **Gross Margin** |
| *(In thousands of U.S. Dollars)* | **2026** | **2026** | **2025** | **2025** | **2026** | **2026** | **2025** | **2025** |
| Content Solutions | $| 31370 | $| 34249 | $| 18320 | $| 23554 |
| Technology Products and Services | 48338 | 48338 | 50593 | 50593 | 26882 | 26882 | 29086 | 29086 |
| Sub-total for reportable segments | 79708 | 79708 | 84842 | 84842 | 45202 | 45202 | 52640 | 52640 |
| All Other | 1671 | 1671 | 1825 | 1825 | 609 | 609 | 536 | 536 |
| Total | $| 81379 | $| 86667 | $| 45811 | $| 53176 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The Company's largest customer for the three months ended March 31, 2026 represented 11% of total Revenues. The Company's largest customer for the three months ended March 31, 2025 represented 15% of total Revenues. No single customer comprised more than 10% of the Company's total Accounts Receivable as of March 31, 2026 or December 31, 2025.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The Company's largest customer for the three months ended March 31, 2026 represented 11% of total Revenues. The Company's largest customer for the three months ended March 31, 2025 represented 15% of total Revenues. No single customer comprised more than 10% of the Company's total Accounts Receivable as of March 31, 2026 or December 31, 2025.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The Company's largest customer for the three months ended March 31, 2026 represented 11% of total Revenues. The Company's largest customer for the three months ended March 31, 2025 represented 15% of total Revenues. No single customer comprised more than 10% of the Company's total Accounts Receivable as of March 31, 2026 or December 31, 2025.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The Company's largest customer for the three months ended March 31, 2026 represented 11% of total Revenues. The Company's largest customer for the three months ended March 31, 2025 represented 15% of total Revenues. No single customer comprised more than 10% of the Company's total Accounts Receivable as of March 31, 2026 or December 31, 2025.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The Company's largest customer for the three months ended March 31, 2026 represented 11% of total Revenues. The Company's largest customer for the three months ended March 31, 2025 represented 15% of total Revenues. No single customer comprised more than 10% of the Company's total Accounts Receivable as of March 31, 2026 or December 31, 2025.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The Company's largest customer for the three months ended March 31, 2026 represented 11% of total Revenues. The Company's largest customer for the three months ended March 31, 2025 represented 15% of total Revenues. No single customer comprised more than 10% of the Company's total Accounts Receivable as of March 31, 2026 or December 31, 2025.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The Company's largest customer for the three months ended March 31, 2026 represented 11% of total Revenues. The Company's largest customer for the three months ended March 31, 2025 represented 15% of total Revenues. No single customer comprised more than 10% of the Company's total Accounts Receivable as of March 31, 2026 or December 31, 2025.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The Company's largest customer for the three months ended March 31, 2026 represented 11% of total Revenues. The Company's largest customer for the three months ended March 31, 2025 represented 15% of total Revenues. No single customer comprised more than 10% of the Company's total Accounts Receivable as of March 31, 2026 or December 31, 2025.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The Company's largest customer for the three months ended March 31, 2026 represented 11% of total Revenues. The Company's largest customer for the three months ended March 31, 2025 represented 15% of total Revenues. No single customer comprised more than 10% of the Company's total Accounts Receivable as of March 31, 2026 or December 31, 2025.* |

---

The following table presents the Costs and Expenses Applicable to Revenues for the Content Solutions segment that is made available to the CODM as part of the Company's annual and quarterly financial reporting requirements in accordance with U.S. GAAP:

---

| | | |
|:---|:---|:---|
| Content Solutions Segment: | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Revenue | $31370 | $34249 |
| &nbsp;&nbsp;Film asset amortization | 3842 | 4339 |
| &nbsp;&nbsp;Marketing and other selling expenses | 5474 | 2435 |
| &nbsp;&nbsp;Co-produced film participation expenses | 79 | 97 |
| &nbsp;&nbsp;Other segment expenses<sup>(1)</sup> | 3655 | 3824 |
| Total Costs and Expenses Applicable to Revenues | 13050 | 10695 |
| Gross Margin | $18320 | $23554 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Included within the Other segment expenses are costs related to film distribution, post-production costs, production costs, and network connectivity fees.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Included within the Other segment expenses are costs related to film distribution, post-production costs, production costs, and network connectivity fees.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Included within the Other segment expenses are costs related to film distribution, post-production costs, production costs, and network connectivity fees.* |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

The following table presents the Costs and Expenses Applicable to Revenues for the Technology Products and Services reportable segment that is made available to the CODM as part of the Company's annual and quarterly financial reporting requirements in accordance with U.S. GAAP:

---

| | | |
|:---|:---|:---|
| Technology Products and Services Segment: | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Revenue | $48338 | $50593 |
| &nbsp;&nbsp;Depreciation of equipment supporting JRSAs | 5969 | 5662 |
| &nbsp;&nbsp;Marketing and other selling expenses | 312 | 246 |
| &nbsp;&nbsp;Write-down of equipment supporting JRSAs | 7 | 88 |
| &nbsp;&nbsp;Write-down of inventory | 50 | 103 |
| &nbsp;&nbsp;Other segment expenses<sup>(1)</sup> | 15118 | 15408 |
| Total Costs and Expenses Applicable to Revenues | 21456 | 21507 |
| Gross Margin | $26882 | $29086 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Included within the Other segment expenses are costs related to the manufacturing and build of IMAX Systems recognized in the period, maintenance and warranty costs, and other product related costs.*  | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Included within the Other segment expenses are costs related to the manufacturing and build of IMAX Systems recognized in the period, maintenance and warranty costs, and other product related costs.*  | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Included within the Other segment expenses are costs related to the manufacturing and build of IMAX Systems recognized in the period, maintenance and warranty costs, and other product related costs.*  |

---

***Geographic Information***

Revenue by geographic area is based on the location of the customer. Revenue related to IMAX Film Remastering process is presented based upon the geographic location of the IMAX System that exhibits the remastered films. IMAX Film Remastering and distribution revenue is generated through contractual relationships with studios and other third parties that may not be in the same geographical location as the IMAX Systems that exhibit the remastered films.

The following table summarizes the Company's revenues by geographic area for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| United States | $29442 | $22571 |
| Greater China | 20568 | 40125 |
| Asia (excluding Greater China) | 12198 | 9291 |
| Western Europe | 11203 | 7553 |
| Latin America | 2544 | 1957 |
| Canada | 2195 | 1402 |
| Rest of the World | 3229 | 3768 |
| Total | $81379 | $86667 |

---

The United States, Greater China (which includes the mainland of the People's Republic of China, Hong Kong, Macau, and Taiwan), Asia (excluding Greater China), and Western Europe each comprise greater than 10% of the Company's total revenues for the three months ended March 31, 2026. The United States, Greater China, and Asia each comprise greater than 10% of the Company's total revenues for the three months ended March 31, 2025.

**14. Employee's Pension and Postretirement Benefits** 

***Defined Benefit Plan***

The Company has an unfunded defined benefit pension plan, the Supplemental Executive Retirement Plan (the "SERP"), covering its CEO, Richard L. Gelfond. Under the terms of his employment agreement, as amended, the total benefit payable to Mr. Gelfond under the SERP is fixed at $20.3 million.

As of March 31, 2026, the Company's projected benefit obligation under the SERP was $17.7 million (December 31, 2025 — $17.5 million). For the three months ended March 31, 2026, the Company recorded interest costs of $0.2 million (2025 — $0.2 million) related to the SERP. The Company expects to recognize additional interest costs of $0.5 million related to the SERP during the remainder of 2026. No contributions are expected to be made to the SERP in 2026.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

***Postretirement Benefits – Executives***

The Company has an unfunded postretirement plan for Mr. Gelfond and Bradley J. Wechsler, former Chairman of the Company's Board of Directors (the "Executive Postretirement Benefit Plan").

As of March 31, 2026, the Company's postretirement benefits obligation under this plan is $0.5 million (December 31, 2025 — $0.5 million). For the three months ended March 31, 2026, the Company has recorded an expense of less than $0.1 million (2025 — less than $0.1 million) related to this plan.

***Postretirement Benefits – Canadian Employees***

The Company has an unfunded postretirement plan for its Canadian employees meeting specific eligibility requirements. The Company will provide eligible participants, upon retirement, with health and welfare benefits. As of March 31, 2026, the Company's postretirement benefits obligation under this plan is $0.9 million (December 31, 2025 — $1.0 million). For the three months ended March 31, 2026, the Company has recorded expense of less than $0.1 million (2025 — less than $0.1 million) related to this plan.

***Deferred Compensation Benefit Plan***

The Company maintained a nonqualified deferred compensation benefit plan (the "Retirement Plan") covering the former CEO of IMAX Entertainment and Senior Executive Vice President of the Company. Under the terms of the Retirement Plan, the benefits were due to vest in full if the executive incurred a separation from service from the Company (as defined therein).

As of March 31, 2026, the benefit obligation related to the Retirement Plan was $4.5 million (December 31, 2025 — $4.4 million) and is recorded on the Company's Condensed Consolidated Balance Sheets within Accrued and Other Liabilities. As the Retirement Plan is fully vested, the benefit obligation is measured at the present value of the benefits expected to be paid in the future with the accretion of interest recognized in the Condensed Consolidated Statements of Operations within Retirement Benefits Non-Service Expense.

The Retirement Plan is funded by an investment in company-owned life insurance ("COLI"), which is recorded at its fair value on the Company's Condensed Consolidated Balance Sheets within Prepaid Expenses. As of March 31, 2026, fair value of the COLI asset was $3.8 million (December 31, 2025 — $3.8 million). Gains and losses resulting from changes in the cash surrender value of the COLI asset are recognized in the Condensed Consolidated Statements of Operations within Realized and Unrealized Investment Gains.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**15. Financial Instruments** 

***Financial Instruments***

The Company's cash is invested with various major financial institutions. The Company's $146.0 million balance of cash and cash equivalents as of March 31, 2026 (December 31, 2025 — $151.2 million) included $139.5 million in cash held outside of Canada (December 31, 2025 — $137.4 million), of which $101.0 million was held in the PRC (December 31, 2025 — $97.2 million).

***Fair Value Measurements***

The carrying values of the Company's Cash and Cash Equivalents, Accounts Receivable, Variable Consideration, Accounts Payable and Accrued Liabilities due within one year approximate their fair values due to the short-term maturity of these instruments. Including these instruments, the Company's financial instruments consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **As of March 31, 2026** | **As of March 31, 2026** | **As of December 31, 2025** | **As of December 31, 2025** |
| *(In thousands of U.S. Dollars)* | **Carrying Amount** | **Estimated Fair Value** | **Carrying Amount** | **Estimated Fair Value** |
| <u>Level 2</u> |  |  |  |  |
| Net financed sales receivables<sup>(1)</sup> | $90124 | $85862 | $90799 | $87677 |
| Net investment in sales-type leases<sup>(1)</sup> | 31201 | 27565 | 31155 | 28200 |
| 2026 Convertible notes<sup>(2)</sup> | (526) | (526) | (743) | (892) |
| 2030 Convertible notes<sup>(2)</sup> | (250000) | (276368) | (250000) | (278708) |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms.* <br>*(2)Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms.* <br>*(2)Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms.* <br>*(2)Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms.* <br>*(2)Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms.* <br>*(2)Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data.* |

---

***Foreign Exchange Risk Management***

The Company is exposed to market risk from changes in foreign currency rates.

A majority of the Company's revenues are denominated in U.S. Dollars while a significant portion of its costs and expenses are denominated in Canadian Dollars. A portion of the Company's net U.S. Dollar cash is converted to Canadian Dollars to fund Canadian Dollar expenses through the spot market. In China and Japan, the Company has ongoing operating expenses related to its operations in RMB, HKD and Japanese Yen, respectively. Net cash flows are converted to and from U.S. Dollars through the spot market. The Company also has cash receipts under leases denominated in RMB, Japanese Yen, Canadian Dollars and Euros which are converted to U.S. Dollars through the spot market. In addition, because IMAX films generate box office receipts in 91 different countries, unfavorable exchange rates between applicable local currencies and the U.S. Dollar could have an impact on box-office receipts and the Company's revenues and results of operations. The Company's policy is to not use any financial instruments for trading or other speculative purposes.

The Company has entered into a series of foreign currency forward contracts to manage the risks associated with the volatility of foreign currencies. Certain of these foreign currency forward contracts met the criteria required for hedge accounting under the Derivatives and Hedging Topic of the FASB ASC at inception, and continued to meet hedge effectiveness tests as of March 31, 2026 (the "Foreign Currency Hedges"), with settlement dates throughout 2026 and 2027. Foreign currency derivatives are recognized and measured on the Condensed Consolidated Balance Sheets at fair value. Changes in the fair value (i.e., gains or losses) are recognized in the Condensed Consolidated Statements of Operations except for derivatives designated and qualifying as foreign currency cash flow hedging instruments. The Company currently has cash flow hedging instruments associated with Selling, General and Administrative Expenses. For foreign currency cash flow hedging instruments related to Selling, General and Administrative Expenses, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in Accumulated Other Comprehensive Loss ("AOCI") and reclassified to the Condensed Consolidated Statements of Operations when the forecasted transaction occurs. Any ineffective portion is recognized immediately in the Condensed Consolidated Statements of Operations.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

The following tabular disclosures reflect the impact that derivative instruments and hedging activities have on the Company's Condensed Consolidated Financial Statements:

<u>Notional value of derivatives in foreign exchange contracts:</u>

---

| | | |
|:---|:---|:---|
| | **March 31,** | **December 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Derivatives designated as hedging instruments: |  |  |
| &nbsp;&nbsp;Foreign exchange contracts — Forwards | $38517 | $48357 |

---

<u>Fair value of derivatives in foreign exchange contracts:</u>

---

| | | | |
|:---|:---|:---|:---|
| | | **March 31,** | **December 31,** |
| *(In thousands of U.S. Dollars)* | **Balance Sheet Location** | **2026** | **2025** |
| Derivatives designated as hedging instruments: |  |  |  |
| &nbsp;&nbsp;Foreign exchange contracts — Forwards | Other assets | $251 | $992 |
|  | Accrued and other liabilities | (232) | (2) |
|  |  | $19 | $990 |

---

<u>Derivatives in foreign currency hedging relationships are as follows:</u>

---

| | | | |
|:---|:---|:---|:---|
| | | **Three Months Ended** | **Three Months Ended** |
| | | **March 31,** | **March 31,** |
| *(In thousands of U.S. Dollars)* |  | **2026** | **2025** |
| Foreign exchange contracts — Forwards | &nbsp;&nbsp;&nbsp;Derivative Loss Recognized in OCI<br>(Effective Portion) | $(631) | $(715) |

---

---

| | | | |
|:---|:---|:---|:---|
| | | **Three Months Ended** | **Three Months Ended** |
| | | **March 31,** | **March 31,** |
| *(In thousands of U.S. Dollars)* | **Location of Derivative Gain (Loss)**<br>**Reclassified from AOCI**<br>**(Effective Portion)** | **2026** | **2025** |
| Foreign exchange contracts — Forwards | &nbsp;&nbsp;&nbsp;Selling, general and <br>administrative expenses | $342 | $(1335) |

---

The Company's estimated net amount of the existing gain as of March 31, 2026 is less than $0.1 million, which is expected to be reclassified to the Condensed Consolidated Statements of Operations within the next twelve months.

**16. Non-Controlling Interests**

***IMAX China Non-Controlling Interest***

As of March 31, 2026, the Company indirectly owned 71.57% of the outstanding equity interests in IMAX China, whose shares trade on the Hong Kong Stock Exchange (December 31, 2025 — 71.57%). IMAX China remains a consolidated subsidiary of the Company. As of March 31, 2026, the balance of the Company's non-controlling interest in IMAX China was $92.2 million (December 31, 2025 — $89.2 million). For the three months ended March 31, 2026, the net income attributable to the non-controlling interest in IMAX China was $1.8 million (2025 — $5.8 million).

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**17. Restructuring and Other Charges**

In the three months ended March 31, 2026, the Company incurred $nil (2025 — $0.1 million) in Restructuring and other charges in the Condensed Consolidated Statements of Operations. In 2025, the charges were related to the assessment of the corporate structure and the resulting internal asset sale.

As of March 31, 2026, the Company's liability was $0.6 million (December 31, 2025 — $1.4 million) on the Consolidated Balance Sheets within Accrued and other liabilities related to Restructuring and other charges.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**Item 2.&nbsp;&nbsp;&nbsp;&nbsp;*Management's Discussion and Analysis of Financial Condition and Results of Operations***

*Presented below is Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") for IMAX Corporation (together with its consolidated subsidiaries, unless the context requires otherwise, "IMAX" or the "Company") for the three months ended March 31, 2026 and 2025. This MD&A should be read in conjunction with the accompanying Condensed Consolidated Financial Statements in Item 1 as well as the Company's audited consolidated financial statements and related notes and the discussion under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" for the fiscal year ended December 31, 2025 included in the Company's 2025 Annual Report on Form 10-K (the "2025 Form 10-K").* 

As of March 31, 2026, the Company indirectly owned 71.57% of the outstanding equity interest in IMAX China Holding, Inc. ("IMAX China"), whose shares trade on the Hong Kong Stock Exchange. IMAX China is a consolidated subsidiary of the Company. For the three months ended March 31, 2026, net income attributable to IMAX China was $6.4 million, of which $4.6 million was attributable to the shareholders of the Company (2025 — $20.4 million and $14.6 million, respectively).

**SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION**

Certain statements included in this quarterly report may constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" within the meaning of Canadian securities laws. Words such as "anticipate," "assume," "believe," "continue," "could," "drive," "estimate," "expect," "forecast," "future," "improve," "likely," "may," "plan," "potential," "project," "projection," "prospect," "remain," "runway," "scheduled," "seek," "strategy," "subject to," "target," "upcoming," "will," or the negative thereof, and similar expressions identify forward-looking statement and information. These forward-looking statements and information include, but are not limited to, statements regarding the Company's business and technology strategies and measures to implement such strategies, including with respect to its brand extensions and re-positionings and new business initiatives; the Company's competitive strengths, goals, market opportunity and penetration, including opportunities in and expected growth from international markets, momentum and runway for expansion and growth of business, networks, operations and technology; future cash flow and revenue realization; capital allocation, including the amount and nature of future capital expenditures and the sufficiency of capital and liquidity to fund the Company's anticipated operating needs; the Company's capital structure, including the incurrence and repayment of debt and the impact of its restrictive debt covenants on operating and financial flexibility; anticipated contributions to pension and postretirement benefit plans; the Company's technological capabilities and the differentiation thereof, including with respect to artificial intelligence ("AI"); the Company's ability to enhance its brand equity and brand awareness and the benefits thereof; industry prospects and developments and shifts in consumer behavior; the Company's upcoming film slate and content pipeline, including the timing and performance thereof; and plans and references to the future success of the Company and expectations regarding its future operating, financial and technological results.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

These forward-looking statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors it believes are appropriate in the circumstances. However, whether actual results and developments will conform with the expectations and predictions of the Company is subject to a number of risks and uncertainties, including, but not limited to: risks associated with the Company's investments, operations and future expansion in foreign jurisdictions, including the impact of economic, political and regulatory policies and laws of the United States, Canada, and China, tariffs and other trade regulations, and economic and trade tensions, trade wars, and geopolitical conflicts; risks related to the Company's growth and operations in China, including industry conditions affecting both the Company and its partners; the ability of the Company's exhibitor customers to fulfill their contractual payment obligations; risks related to the Company's ability to attract and retain its employee population or the loss of the Company's key personnel; the performance of IMAX remastered films and other films released to the IMAX network; conditions, changes and developments in the commercial exhibition industry; the Company's ability to enter into new IMAX theater system agreements and sales and lease agreements and the effects thereof ; fluctuations in operating results and cash flow ; currency fluctuations and foreign exchange controls; the potential impact of increased competition in the markets within which the Company operates, including competitive actions by other companies; the ability of the Company to respond to change and advancements in technology, including with respect to AI products and AI-generated content; the potential impacts of consolidation among commercial exhibitors and studios; success of brand extensions and new business initiatives; conditions and competition in the in-home (including streaming) and out-of-home entertainment industries; the Company's ability to identify and pursue new business opportunities (or lack thereof); cybersecurity and data privacy incidents; the Company's ability to protect its intellectual property and to avoid infringing, misappropriating, or violating the intellectual property rights of others; effects of environmental laws and regulations, including with respect to climate change; weather conditions and natural disasters that may disrupt or harm the Company's business; effects of the Company's indebtedness on its cash flow and business activities and the Company's ability to comply with its debt agreements; general economic, market or business conditions; sustained inflationary pressure; political, economic and social instability and the resulting disruptions to the Company's operations or supply chain; the Company's ability to convert system backlog into revenue and cash flows; accuracy of assumptions underlying goodwill impairment assessment and fair value measurements; changes in laws, regulations or accounting principles; any statements of belief and any statements of assumptions underlying any of the foregoing; other factors and risks outlined in the Company's periodic filings with the United States Securities and Exchange Commission (the "SEC") or in Canada, the System for Electronic Data Analysis and Retrieval ("SEDAR+"); and other factors, many of which are beyond the control of the Company. Consequently, all of the forward-looking statements made in this quarterly report are qualified by these cautionary statements, and actual results or anticipated developments by the Company may not be realized, and even if substantially realized, may not have the expected consequences to, or effects on, the Company. The forward-looking statements herein are made only as of the date hereof and the Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events or otherwise.

IMAX<sup>®</sup>, IMAX<sup>®</sup> 3D, Experience It In IMAX<sup>®</sup>, *The* IMAX *Experience*<sup>®</sup>, DMR<sup>®</sup>, Filmed For IMAX<sup>®</sup>, IMAX Live<sup>®</sup>, and IMAX Enhanced<sup>®</sup> are trademarks and trade names of the Company or its subsidiaries that are registered or otherwise protected under laws of various jurisdictions.<br>

The Company makes available, free of charge, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and any amendments to such reports, as soon as reasonably practicable after such filings have been made with the SEC and Canadian securities regulators. Reports may be obtained free of charge through the SEC's website at www.sec.gov or the SEDAR+ website at www.sedarplus.ca and through the Company's website at www.imax.com or by calling the Company's Investor Relations Department at 212-821-0154.

The Company announces material information to the public through a variety of means, including filings with the SEC and Canadian securities regulators, press releases, public conference calls, and its website at www.imax.com. The Company uses these channels to communicate with investors and the public about the Company, its products and services, and other matters. Therefore, investors are encouraged to review the information the Company makes public in these locations, as such information could be deemed to be material information. No information included on the Company's website shall be deemed included or otherwise incorporated into this filing, except where expressly indicated. All references to the Company's website are intended to be inactive textual references only.

**OVERVIEW**

IMAX is a premier global technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers a unique end-to-end solution to create superior, awe-inspiring immersive content experiences for which the IMAX<sup>®</sup> brand is globally renowned. Top filmmakers, movie studios, artists, and creators utilize the cutting-edge visual and sound technology of IMAX to connect with audiences in innovative ways. As a

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

result, IMAX is among the most important and successful global distribution platforms for domestic and international tentpole films. The Company's global content portfolio includes blockbuster films, both from Hollywood and local language film industries worldwide; IMAX documentaries, both original and acquired ("IMAX Documentaries"); and IMAX events and experiences in emerging verticals, including music, gaming, and sports.

The Company leverages its proprietary technology and engineering in its business, which principally consists of the digital remastering of films and other content into the IMAX format for distribution across the IMAX network ("IMAX Film Remastering") and the sale or lease of premium IMAX theater systems ("IMAX System(s)").

IMAX Systems are based on proprietary and patented image, audio and other technology developed over the course of the Company's history. The customers for IMAX Systems are principally exhibitors that operate commercial multiplex theaters, and, to a much lesser extent, institutional locations, including museums and science centers, and destination entertainment sites. The Company does not own the locations in the IMAX network, except for one, and is not an exhibitor, but instead sells or leases the IMAX System to exhibitor customers along with licenses to use its trademarks and ongoing maintenance services for which there are annual payments by the exhibitors to IMAX.

IMAX has the largest global premium format network, more than double the size of its nearest competitor. As of March 31, 2026, there were 1,865 IMAX Systems operating in locations in 91 countries and territories, including 1,798 commercial multiplexes, 10 commercial destinations, and 57 institutional locations in the Company's global network. This compares to 1,810 IMAX Systems operating in locations in 89 countries and territories as of March 31, 2025, including 1,738 commercial multiplexes, 11 commercial destinations, and 61 institutional locations in the Company's global network. Refer to the table under "IMAX Network and Backlog" for additional information on the composition of the IMAX network.

IMAX Systems provide the Company's exhibitor customers with a combination of the following benefits:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the ability to exhibit content that has been enhanced through the IMAX Film Remastering process, which results in higher image and sound fidelity than conventional cinema experiences;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• advanced, high-resolution projectors with specialized equipment and automated theater control systems, which generate significantly more contrast and brightness than conventional theater systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• large screens and proprietary auditorium geometry, which result in a substantially larger field of view than conventional theater systems so that the screen extends to the edge of a viewer's peripheral vision and creates more realistic images;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• advanced sound system components, which deliver more expansive sound imagery than conventional theater systems and pinpointed origination of sound to any specific spot in an auditorium equipped with an IMAX System;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• specialized theater acoustics, which result in a four-fold reduction in background noise compared to conventional cinema experiences;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ongoing maintenance and extended warranty services to ensure a consistent image and sound quality presentation across the IMAX global network; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a license to the globally recognized IMAX brand, as well as benefits from IMAX marketing of films being shown in its network and IMAX's growing social media followership.

&nbsp;&nbsp;&nbsp;&nbsp;

The Company believes that the benefits related to the enhanced and differentiated image quality and film aspect ratio enable audiences in IMAX locations to feel as if they are a part of the on-screen action, creating a more intense, immersive, and awe-inspiring experience than a conventional cinematic format. For additional discussion, see section titled "IMAX Film Remastering and Distribution" below.

As a result of the engineering and scientific achievements that are a hallmark of *The* IMAX *Experience*<sup>®</sup>, the Company's exhibitor customers typically charge a premium for films released in IMAX's format versus films exhibited in their other auditoriums. The premium pricing, combined with the higher attendance levels associated with IMAX films, generates incremental box office receipts ("global box office") for the Company's exhibitor customers and for the movie studios releasing their films to the IMAX network. IMAX has become a key premium distribution and marketing platform for Hollywood and local language films driven by IMAX's leading global network footprint and scale, the incremental global box office generated by IMAX films and the growing demand by moviegoers for the differentiated quality of *The* IMAX *Experience*.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

The Company achieved global box office of $260 million in the first quarter of 2026. The Company's first quarter global box office was derived from 34 pieces of content distributed across its global network. The first quarter was highlighted by the performance of the carry-over of *Avatar: Fire and Ash* that drove record January global box office and the March release of the Filmed For IMAX<sup>®</sup> title *Project Hail Mary*, in which IMAX captured 20% of the opening weekend global box office, despite IMAX representing less than 1% of screens worldwide. The Company continues to expand its local language strategy with 17 releases across 9 countries, including a first in Taiwan, with total first quarter local language box office of $62 million (or 24% of global box office), led by Chinese film, *Pegasus 3.* Despite increasing competition for consumer attention across both out-of-home and in-home entertainment, demand for *The* IMAX *Experience* continues to strengthen among theatergoers. During the first quarter of 2026, the Company's trailing twelve month domestic box office market share was 5.4% and global market share was 3.8%. See "Results of Operations" below for a discussion of the Company's first quarter 2026 results as compared to the prior year period.

**Recent Developments**

As announced on March 30, 2026, Richard Gelfond, the Company's Chief Executive Officer, is on a temporary medical leave of absence. On April 16, 2026, the Company appointed Robert D. Lister, its Chief Legal Officer and Senior Executive Vice President, to serve as the Company's interim principal executive officer ("PEO") in addition to his current duties until May 1, 2026, following which Mr. Gelfond will resume the role of PEO. Mr. Gelfond has been gradually re-engaging in the Company's business and is involved in all strategic decisions. Until his leave is over, the Company's management team will continue with its day-to-day responsibilities in coordination with Mr. Gelfond. (Refer to "Risk Factors—The loss of one or more of the Company's key personnel, or its failure to attract and retain its employee population, could adversely affect its business." in Part I, Item 1A. in the 2025 Form 10-K.)

**SOURCES OF REVENUE**

The Company has organized its operating segments into the following two reportable segments: (i) Content Solutions, which principally includes content enhancement and distribution services, and (ii) Technology Products and Services, which principally includes the sale, lease, and maintenance of IMAX Systems. The Company's activities that do not meet the criteria to be considered a reportable segment are disclosed within All Other (See Note 13 of Notes to Condensed Consolidated Financial Statements in Part I, Item 1).

**Content Solutions**

The Content Solutions segment earns revenue from IMAX Film Remastering, including the distribution of this content across the IMAX global network. To a lesser extent, the Content Solutions segment also earns revenue from the distribution of large-format documentary films and IMAX events and experiences, including music, gaming, and sports to commercial IMAX theaters, as well as the provision of film post-production services.

Content Solutions segment results are influenced by the level of commercial success and global box office performance of the films and other content released to the IMAX network, as well as other factors, including the timing of the releases, the timing of documentary downstream sales, the length of play across the IMAX network, the global box office share take rates under the Company's Film Remastering and distribution arrangements, the level of marketing spend associated with the releases in the year, and fluctuations in the value of foreign currencies versus the U.S. Dollar.

*Film Remastering and Distribution*

IMAX Film Remastering is a proprietary technology that digitally remasters films and other content into IMAX formats for distribution across the IMAX network. In a typical IMAX Film Remastering and distribution arrangement, the Company receives a percentage of the global box office from a studio in exchange for converting a commercial film into the IMAX format and distributing it through the IMAX network. The fee earned by the Company in a typical IMAX Film Remastering and distribution arrangement averages approximately 12.5% of box office on a gross basis before sales taxes except within Greater China, where the Company often receives a lower percentage of net box office due to an incremental importation fee paid by the studios. All of the Company's box office results in this Form 10-Q are inclusive of China booking fees to be consistent with market reporting of global box office.

IMAX Film Remastering digitally enhances the image quality and/or resolution for projection on IMAX screens while maintaining or enhancing the visual clarity and sound quality to levels for which *The* IMAX *Experience* is known. IMAX Film Remastering is completed for the image of films released to the IMAX network, creating a unique IMAX version that is optimized for IMAX's proprietary digital projection systems and format. In addition, the original soundtrack of a film to be exhibited across the IMAX locations is remastered into a unique IMAX digital audio format. IMAX sound systems use proprietary loudspeaker systems, designs and proprietary surround sound configurations to ensure every seat in an auditorium is an optimal listening position.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

IMAX films also benefit from enhancements made by individual filmmakers exclusively for the IMAX release of the film. Collectively, the Company refers to these enhancements as "IMAX DNA." Filmmakers and movie studios increasingly seek to infuse more IMAX DNA in theatrical releases to realize a filmmaker's creative vision more fully, while generating interest and excitement among moviegoers. Such enhancements include shooting films with IMAX cameras to increase the audience's immersion in the film and to take advantage of the unique dimensions of the IMAX screen by projecting the film in a larger aspect ratio that delivers up to 26% more image onto a standard IMAX movie screen versus a conventional screen. In select IMAX locations worldwide, movies filmed with IMAX cameras have an IMAX-exclusive 1.43 film aspect ratio, delivering up to 67% more image onto a standard conventional movie screen.

Filmed For IMAX is IMAX's filmmaker partnership program. Filmmakers who participate in the program leverage IMAX technology throughout the production process to deliver a movie that is meant to be seen in an IMAX location. From pre-production through to release, the Company works closely with filmmakers to maximize *The* IMAX *Experience* for audiences. Filmed For IMAX movies are shot using either an IMAX certified digital camera or an IMAX film camera, with the IMAX Post-Production team working closely with the filmmaker from camera testing before the shoot begins, to on-set support, to test screenings, and post-production. Most Filmed For IMAX movies leverage IMAX's exclusive expanded aspect ratio for select sequences and, occasionally, the entire film, and benefit from unique marketing support. The global box office metrics have demonstrated audiences respond extremely favorably to Filmed For IMAX titles, resulting in a higher market share for IMAX. In the first quarter of 2026, Filmed For IMAX titles on average indexed over 14% higher than titles with no IMAX DNA.

Management believes that growth in global box office represents an important growth opportunity for the Company. The Company's strategy to capitalize on this opportunity includes expanding the IMAX network into underpenetrated international markets and growing the number of local language films released, particularly in Japan, India, South Korea, and France. As the popularity of local language films has continued to increase, the Company has extended its content strategy to distribute local language content beyond native markets. For the three months ended March 31, 2026, local language films exhibited across the Company's global network generated $62 million in box office, representing 24% of the Company's global box office.

The following table provides the number of new films and other content released to the Company's global network during the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| | **2026** | **2025** |
| Hollywood film releases<sup>(1)</sup> | 7 | 7 |
| Local language film releases: |  |  |
| &nbsp;&nbsp;Japan | 5 | 3 |
| &nbsp;&nbsp;China | 3 | 6 |
| &nbsp;&nbsp;India | 2 | 5 |
| &nbsp;&nbsp;South Korea | 2 | 2 |
| &nbsp;&nbsp;France | 1 | 2 |
| &nbsp;&nbsp;Vietnam | 1 | 1 |
| &nbsp;&nbsp;Indonesia | 1 | 1 |
| &nbsp;&nbsp;Thailand | 1 |  |
| &nbsp;&nbsp;Taiwan | 1 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total local language film releases | 17 | 20 |
| Other content experiences | 7 | 6 |
|  | 31 | 33 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)For the three months ended March 31, 2026, the films released to the Company's global network include four with IMAX DNA (2025 — two).* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)For the three months ended March 31, 2026, the films released to the Company's global network include four with IMAX DNA (2025 — two).* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)For the three months ended March 31, 2026, the films released to the Company's global network include four with IMAX DNA (2025 — two).* |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

In addition to the 31 IMAX new films and other content experiences released on the Company's global network during the three months ended March 31, 2026, the Company has announced the following 34 new films and other content experiences for release in the remainder of 2026:

---

| | | | |
|:---|:---|:---|:---|
| **Title** | **Studio** | **Scheduled**<br>**Release Date**<sup>(1)</sup> | **IMAX DNA** |
| *The Super Mario Galaxy Movie* | Universal Pictures | April 2026 |  |
| *Detective Conan: Fallen Angels of the Highway*<sup>(2)</sup> | Toho Cinemas | April 2026 |  |
| *Lee Cronin's The Mummy* | Warner Bros. Pictures | April 2026 |  |
| *Michael* | Lionsgate | April 2026 |  |
| *Sakamoto Days*<sup>(2)</sup> | Toho Cinemas | April 2026 |  |
| *2DIE4*<sup>(2)</sup> | Abdala Brothers | April 2026 |  |
| *Whisper of the Heart 4K IMAX*<sup>(2)</sup> | Studio Ghibli | April 2026 |  |
| *Cold War 1994*<sup>(2)</sup> | Ruyi Film | May 2026 |  |
| *F1*<sup>®</sup> *on Apple TV Live in IMAX:Miami Race* | Apple TV | May 2026 |  |
| *Mortal Kombat II* | Warner Bros. Pictures | May 2026 | Filmed for IMAX |
| *Top Gun 40*<sup>th</sup> *Anniversary* | Paramount Pictures | May 2026 |  |
| *The Secret World of Arrietty 4K IMAX*<sup>(2)</sup> | Studio Ghibli | May 2026 |  |
| *The Mandalorian and Grogu* | Walt Disney Studios | May 2026 | Filmed for IMAX |
| *F1*<sup>®</sup> *on Apple TV Live in IMAX:Monaco Race* | Apple TV | June 2026 |  |
| *Disclosure Day* | Universal Pictures | June 2026 |  |
| *Toy Story 5* | Walt Disney Studios | June 2026 |  |
| *Supergirl* | Warner Bros. Pictures | June 2026 | Filmed for IMAX |
| *Minions & Monsters* | Universal Pictures | July 2026 |  |
| *F1*<sup>®</sup> *on Apple TV Live in IMAX:Silverstone Race* | Apple TV | July 2026 |  |
| *Moana* | Walt Disney Pictures | July 2026 |  |
| *The Odyssey* | Universal Pictures | July 2026 | Filmed for IMAX |
| *The End of Oak Street* | Warner Bros. Pictures | August 2026 | Filmed for IMAX |
| *The Dog Stars* | Walt Disney Pictures | August 2026 |  |
| *F1*<sup>®</sup> *on Apple TV Live in IMAX:Monza Race* | Apple TV | September 2026 |  |
| *Resident Evil* | Sony Pictures | September 2026 | Filmed for IMAX |
| *Digger* | Warner Bros. Pictures | October 2026 |  |
| *Street Fighter*<sup>(2)</sup> | Paramount Pictures | October 2026 | Filmed for IMAX |
| *F1*<sup>®</sup> *on Apple TV Live in IMAX:Austin Race* | Apple TV | October 2026 |  |
| *Godzilla Minus Zero*<sup>(2)</sup> | Toho Cinemas | November 2026 | Filmed for IMAX |
| *The Great Beyond* | Warner Bros. Pictures | November 2026 |  |
| *Hunger Games: Sunrise on the Reaping* | Lionsgate | November 2026 |  |
| *Narnia* | Netflix | November 2026 | Filmed for IMAX |
| *Avengers: Doomsday*<sup>(2)</sup> | Walt Disney Studios | December 2026 |  |
| *Dune: Part Three* | Warner Bros. Pictures | December 2026 | Filmed for IMAX |
| *Ramayana*<sup>(2)</sup> | DNEG | TBD | Filmed For IMAX |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The scheduled release dates in the table above are subject to change, may vary by territory, and may not reflect the date(s) of limited premiere events.*<br>*(2)Denotes local language release.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The scheduled release dates in the table above are subject to change, may vary by territory, and may not reflect the date(s) of limited premiere events.*<br>*(2)Denotes local language release.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The scheduled release dates in the table above are subject to change, may vary by territory, and may not reflect the date(s) of limited premiere events.*<br>*(2)Denotes local language release.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The scheduled release dates in the table above are subject to change, may vary by territory, and may not reflect the date(s) of limited premiere events.*<br>*(2)Denotes local language release.* |

---

The Company remains in active negotiations with studios for additional films to fill out its short- and long-term film slate for the IMAX network. The Company also expects to announce additional local language films and exclusive IMAX events and experiences to be released to its global network in 2026.

*Other Content Solutions*

The Company distributes large-format documentary feature films through its global commercial network and institutional theaters. Traditionally, the Company receives as its distribution fee either a fixed amount or a fixed percentage of the theater global box office and, following the recoupment of its costs, is typically entitled to receive an additional percentage of gross revenues as participation revenues.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

The Company believes that the IMAX network is a valuable global platform to launch and distribute original content, including documentaries. The ownership rights to such films may be held by the film sponsors, the film investors and/or the Company. As of March 31, 2026, the Company had distribution rights with respect to approximately 75 films, which cover subjects such as space, wildlife, music, sports, history, and natural wonders.

In early 2026, *The Lost Wolves of Yellowstone*, in collaboration with Grizzly Creek Films LLC, and French language documentary *Athos,* produced by Federation Studio France, were released. In 2026, the Company plans to release the documentary *Portrait of an Artist* in collaboration with The National Basketball Association ("NBA"), Unanimous Media, and Religion of Sports, offering an intimate glimpse into the life of NBA superstar Stephen Curry*.* Upcoming 2026 documentaries which are currently in production include *Stormbound,* produced by Academy Award-winning producer, Adam McKay; and *Frontier,* produced in collaboration with Nocturnal Entertainment Productions, LLC, Atlas Entertainment LL, and Believe Entertainment Group, LLC. *The Elephant Odyssey*, a documentary in collaboration with Beach House Pictures Pte Ltd and China International Communications Group, is expected to be released in 2027.

In addition, the Company continues to evolve its platform to bring new, innovative IMAX events and experiences to audiences worldwide. As of March 31, 2026, the Company has 252 connected IMAX locations worldwide. Furthermore, the Company can use its live streaming technologies to deliver events to additional IMAX locations around the world.

In the three months ended March 31, 2026, the Company partnered with Neon Rated and Universal Pictures on the release of *EPiC: Elvis Presley in Concert.* The Company also partnered with Bleecker Street and Universal Pictures for the release of *Stray Kids: The dominATE Experience,* and with Trafalgar for release of *Twenty One Pilots: More Than We Ever Imagined.* In addition, the Company partnered with Mercury Studios for a two-night-only screening of *Eric Church: Evangeline vs. The Machine Comes Alive,* and with Sony Pictures for the two-night-only screening of *TOMMY in IMAX (50th Anniversary)*. The Company also partnered with A24 for a limited release of *Marty Supreme* across approximately 150 IMAX locations in the United States, Australia, and New Zealand. In March 2026, the Company partnered with MGM Studios for an exclusive Q&A livestream in advance of the screening of *Project Hail Mary* across a limited number connected IMAX locations in North America.

The Company provides film post-production and quality control services for films, whether produced by IMAX or third parties, and digital post-production services. In addition, the Company also provides IMAX film and digital cameras to content creators under the IMAX certified camera program.

**Technology Products and Services**

The Technology Products and Services segment earns revenue principally from the sale or lease of IMAX Systems, as well as from the maintenance of IMAX Systems. To a lesser extent, the Technology Products and Services segment also earns revenue from certain ancillary theater business activities, including after-market sales of IMAX Systems parts and 3D glasses.

The primary drivers of Technology Products and Services segment results are the number of IMAX Systems installed in a period, the costs associated with each installation, and lease payments tied to the global box office performance of the films released to the IMAX network, as well as the associated maintenance contracts that accompany each installation. The average revenue and gross margin per IMAX System under sale and sales-type lease arrangements vary depending upon the number of IMAX System commitments with a single respective exhibitor, an exhibitor's location, the type of IMAX System sold, and various other factors. The installation of IMAX Systems in theaters or multiplexes, which make up a large portion of the Company's system backlog, depends primarily on the timing of the construction of those projects, which is not under the Company's control.

*Sales and Sales-Type Lease Arrangements*

The Company provides IMAX Systems to exhibitors through sale arrangements or long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX System, the Company earns initial fees and ongoing consideration, which can include fixed annual minimum payments and contingent fees in excess of the minimum payments, as well as maintenance and extended warranty fees (see "IMAX Maintenance" below). The initial fees vary depending on the system configuration and location of the IMAX System. Initial fees are paid to the Company in installments typically between the time of signing the arrangement and the time of system installation. Once an IMAX System is installed, the initial fees and the present value of future annual minimum payments, which are financing fees, are recognized as revenue. In addition, in sale arrangements, the present value of the estimated contingent fees that may become due if certain annual minimum global box office receipt thresholds are exceeded is recorded as revenue in the period when the sale is recognized and is adjusted in future periods based on actual results and changes in estimates. Such variable consideration is only recognized on sales transactions to the extent the Company believes there is not a risk of significant revenue reversal. Finance income is recognized over the term of a financed sale or sales-type lease arrangement.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

In sale arrangements, title to the IMAX System equipment generally transfers to the customer. However, in certain instances, the Company retains title or a security interest in the equipment until the customer has made all payments required by the agreement or until certain shipment events for the equipment have occurred. In a sales-type lease arrangement, title to the IMAX System equipment remains with the Company. The Company has the right to remove the equipment for non-payment or other defaults by the customer.

The revenue earned from customers under the Company's IMAX System sale or sales-type lease agreements varies from quarter-to- quarter and year-to-year based on a number of factors, including the number and mix of IMAX System configurations sold or leased, the timing of installation of the IMAX Systems, the nature of the arrangement and other factors specific to individual contracts.

*Joint Revenue Sharing Arrangements*

The Company also provides IMAX Systems to exhibitors through joint revenue sharing arrangements "JRSA(s)". Under the traditional form of these arrangements, the Company provides the IMAX System under a long-term lease in which the Company assumes the majority of the equipment and installation costs. In exchange for its upfront investment, the Company, generally, earns rent based on a percentage of contingent box office receipts rather than requiring the customer to pay a fixed upfront fee or fixed annual minimum payments. Rental payments from the customer are required throughout the term of the arrangement and are typically due either monthly or quarterly. The Company retains title to the IMAX System equipment components throughout the lease term, and the equipment is returned to the Company at the conclusion of the arrangement.

Under certain other JRSAs, known as hybrid arrangements, the customer is responsible for making fixed upfront payments prior to the delivery and installation of the IMAX System in an amount that is typically half of what the Company would receive from a typical sale transaction. As with a traditional JRSA, the customer also pays the Company a percentage of contingent box office receipts over the term of the arrangement, although this percentage is typically half that of a traditional JRSA.

Under most JRSAs (both traditional and hybrid), the initial non-cancellable term is 10 years or longer and is renewable by the customer for one to two additional terms of between three to five years. The Company has the right to remove the equipment for non-payment or other defaults by the customer. The contracts are non-cancellable by the customer unless the Company fails to perform its material obligations.

The revenue earned from customers under the Company's JRSAs can vary from quarter-to-quarter and year-to-year based on a number of factors that drive global box office levels including film performance, the mix of IMAX System configurations, the timing of installation of IMAX Systems, the nature of the arrangement, the location, size and management of the theater and other factors specific to individual arrangements.

JRSAs also require IMAX to provide maintenance and extended warranty services to the customer over the term of the lease in exchange for a separate fixed annual fee. These fees are reported within IMAX Maintenance, as discussed below.

JRSAs have been an important factor in the expansion of the Company's commercial system network. JRSAs allow commercial theater exhibitors to install IMAX Systems without the significant initial capital investment required in a sale or sales-type lease arrangement. JRSAs drive recurring cash flows and earnings for the Company as customers under these arrangements pay the Company a portion of their ongoing box office receipts. The Company funds its investment in equipment for JRSAs through cash flows from operations. As of March 31, 2026, the Company had 881 locations under JRSAs in its global commercial multiplex network. The Company also had contracts in backlog for 255 IMAX systems under JRSAs as of March 31, 2026, including 149 new locations and 106 upgrades to existing locations.

*IMAX Maintenance*

IMAX System arrangements also include a requirement for the Company to provide maintenance services over the life of the arrangement in exchange for an extended warranty and annual maintenance fee paid by the exhibitor. Under these arrangements, the Company provides preventative and emergency maintenance services to ensure that each presentation is up to IMAX quality standards. Annual maintenance fees are paid throughout the duration of the term of the system agreements.

**All Other**

*Streaming and Consumer Technology*

IMAX's Streaming and Consumer Technology ("SCT") business offers a single unified program: IMAX Enhanced<sup>®</sup>. This umbrella program builds on IMAX's brand and proprietary VisionScience™ technology to deliver *The* IMAX *Experience* to users across streaming platforms and consumer devices. The new IMAX Enhanced program for partners includes three core elements:

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.IMAX Enhanced Live: Real-time enhancement for sports, concerts, and events using SCT's proprietary technology to measure, enhance, optimize, and validate premium color, contrast, and clarity at the speed of live.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.IMAX Enhanced On-Demand: Quality preservation and optimization for films and series to preserve creative intent with IMAX-calibrated fidelity and remastering, offering viewers a differentiated, premium IMAX-assured experience. IMAX Enhanced on-demand content is currently available for fan-favorite titles across leading services such as Disney+, Sony Pictures Core, and Tencent Video.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Device Certification & Calibration: Establishes IMAX quality standards for consumer devices to ensure playback meets IMAX benchmarks. It assures that the enhancement and preservation of quality applied upstream for both Live and On-Demand workflows are maintained faithfully and experienced as intended on consumer devices. As of March 31, 2026, IMAX Enhanced certified devices in-market are with partners including Sony Electronics, Hisense, TCL, LG, and Philips.

The SCT products previously branded as StreamSmart™ (encoding optimization) and StreamAware™ (quality assurance and monitoring) have been integrated into the IMAX Enhanced program, streamlining operations and enabling partners to deliver premium viewing experiences validated through IMAX's proprietary quality standards.

IMAX's SCT represents an extension of the IMAX brand and technology beyond traditional theatrical programming into live streaming for connected theaters and live and on-demand streaming home entertainment experiences. Leveraging IMAX's globally recognized brand and proprietary technology, IMAX Enhanced is designed to drive consumer engagement and create incremental return on investment for content owners and rights holders.

*Other*

All Other also includes revenues from sources including one owned and operated IMAX System in Sacramento, California; a commercial arrangement with one theater resulting in the sharing of profits and losses; the provision of management services to three other theaters; and merchandising revenue.

**IMAX NETWORK AND BACKLOG** 

*IMAX Network*

The following table provides detailed information about the IMAX network by type and geographic location as of March 31, 2026 and 2025. For additional information regarding the composition of the IMAX network, see "Marketing and Customers" in Part I, Item 1 of the Company's 2025 Form 10-K.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** |
| | **Commercial** <br>**Multiplex** | **Commercial**<br>**Destination** | **Institutional** | **Total** | **Commercial** <br>**Multiplex** | **Commercial**<br>**Destination** | **Institutional** | **Total** |
| United States | 385 | 4 | 24 | 413 | 372 | 4 | 24 | 400 |
| Canada | 41 | 1 | 5 | 47 | 44 | 1 | 5 | 50 |
| Greater China<sup>(1)</sup> | 798 |  | 12 | 810 | 793 |  | 13 | 806 |
| Asia (excluding <br>Greater China) | 204 | 1 | 2 | 207 | 186 | 1 | 2 | 189 |
| Western Europe | 154 | 3 | 7 | 164 | 136 | 4 | 8 | 148 |
| Latin America<sup>(2)</sup> | 64 | 1 | 6 | 71 | 62 | 1 | 7 | 70 |
| Rest of the World | 152 |  | 1 | 153 | 145 |  | 2 | 147 |
| Total<sup>(3)</sup> | 1798 | 10 | 57 | 1865 | 1738 | 11 | 61 | 1810 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Greater China includes China, Hong Kong, Taiwan, and Macau.*<br>*(2)Latin America includes South America, Central America, and Mexico.*<br>*(3)Period-to-period changes in the table above are reported net of the effect of permanently closed locations.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Greater China includes China, Hong Kong, Taiwan, and Macau.*<br>*(2)Latin America includes South America, Central America, and Mexico.*<br>*(3)Period-to-period changes in the table above are reported net of the effect of permanently closed locations.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Greater China includes China, Hong Kong, Taiwan, and Macau.*<br>*(2)Latin America includes South America, Central America, and Mexico.*<br>*(3)Period-to-period changes in the table above are reported net of the effect of permanently closed locations.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Greater China includes China, Hong Kong, Taiwan, and Macau.*<br>*(2)Latin America includes South America, Central America, and Mexico.*<br>*(3)Period-to-period changes in the table above are reported net of the effect of permanently closed locations.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Greater China includes China, Hong Kong, Taiwan, and Macau.*<br>*(2)Latin America includes South America, Central America, and Mexico.*<br>*(3)Period-to-period changes in the table above are reported net of the effect of permanently closed locations.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Greater China includes China, Hong Kong, Taiwan, and Macau.*<br>*(2)Latin America includes South America, Central America, and Mexico.*<br>*(3)Period-to-period changes in the table above are reported net of the effect of permanently closed locations.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Greater China includes China, Hong Kong, Taiwan, and Macau.*<br>*(2)Latin America includes South America, Central America, and Mexico.*<br>*(3)Period-to-period changes in the table above are reported net of the effect of permanently closed locations.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Greater China includes China, Hong Kong, Taiwan, and Macau.*<br>*(2)Latin America includes South America, Central America, and Mexico.*<br>*(3)Period-to-period changes in the table above are reported net of the effect of permanently closed locations.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Greater China includes China, Hong Kong, Taiwan, and Macau.*<br>*(2)Latin America includes South America, Central America, and Mexico.*<br>*(3)Period-to-period changes in the table above are reported net of the effect of permanently closed locations.* |

---

(See "Risk Factors – The Company faces risks in connection with its significant presence in China and the continued expansion of its business there," "Risk Factors – The Company may not convert all of its backlog into revenue and cash flows," and "Risk Factors – General political, social and economic conditions can affect the Company's business by reducing both revenues generated from existing IMAX Systems and the demand for new IMAX Systems" in Part I, Item 1A of the Company's 2025 Form 10-K.)

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

IMAX currently estimates a worldwide commercial multiplex addressable market of 4,466 locations, of which there are 1,798 IMAX Systems operating as of March 31, 2026, representing a market penetration of only 40%. The Company believes that the majority of its future growth will come from international markets. As of March 31, 2026, 76% of IMAX Systems in the global commercial multiplex network were located within international markets (defined as all countries other than the United States and Canada). Revenues and gross box office ("GBO") derived from international markets continue to exceed revenues and GBO from the United States and Canada. Risks associated with the Company's international business are outlined in "Risk Factors – The Company conducts business internationally, which exposes it to uncertainties and risks that could negatively affect its operations, sales and future growth prospects" in Part II, Item 1A of this Form 10-Q.

The following tables provide detailed information about IMAX Systems operating in multiplex locations by arrangement type and geographic location as of March 31, 2026 and 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| | **Commercial Multiplex Locations in IMAX Network** | **Commercial Multiplex Locations in IMAX Network** | **Commercial Multiplex Locations in IMAX Network** | **Commercial Multiplex Locations in IMAX Network** |
| | **Traditional**<br>**JRSA** | **Hybrid**<br>**JRSA** | **Sales** <br>**Arrangements**<sup>(1)</sup> | <br>**Total** |
| Domestic Total (United States & Canada) | 277 | 3 | 146 | 426 |
| International: |  |  |  |  |
| &nbsp;&nbsp;Greater China | 395 | 67 | 336 | 798 |
| &nbsp;&nbsp;Asia (excluding Greater China) | 58 | 1 | 145 | 204 |
| &nbsp;&nbsp;Western Europe | 50 | 13 | 91 | 154 |
| &nbsp;&nbsp;Latin America | 5 |  | 59 | 64 |
| &nbsp;&nbsp;Rest of the World | 12 |  | 140 | 152 |
| &nbsp;&nbsp;&nbsp;&nbsp;International Total | 520 | 81 | 771 | 1372 |
| Worldwide Total<sup>(2)(3)</sup> | 797 | 84 | 917 | 1798 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Period-to-period changes in the tables above are reported net of permanently closed systems.*<br>*(3)Includes 31 IMAX Systems that were converted from Hybrid JRSA arrangement types to Sales Arrangements during the three months ended March 31, 2026.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Period-to-period changes in the tables above are reported net of permanently closed systems.*<br>*(3)Includes 31 IMAX Systems that were converted from Hybrid JRSA arrangement types to Sales Arrangements during the three months ended March 31, 2026.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Period-to-period changes in the tables above are reported net of permanently closed systems.*<br>*(3)Includes 31 IMAX Systems that were converted from Hybrid JRSA arrangement types to Sales Arrangements during the three months ended March 31, 2026.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Period-to-period changes in the tables above are reported net of permanently closed systems.*<br>*(3)Includes 31 IMAX Systems that were converted from Hybrid JRSA arrangement types to Sales Arrangements during the three months ended March 31, 2026.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Period-to-period changes in the tables above are reported net of permanently closed systems.*<br>*(3)Includes 31 IMAX Systems that were converted from Hybrid JRSA arrangement types to Sales Arrangements during the three months ended March 31, 2026.* |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** |
| | **Commercial Multiplex Locations in IMAX Network** | **Commercial Multiplex Locations in IMAX Network** | **Commercial Multiplex Locations in IMAX Network** | **Commercial Multiplex Locations in IMAX Network** |
| | **Traditional**<br>**JRSA** | **Hybrid**<br>**JRSA** | **Sales** <br>**Arrangements**<sup>(1)</sup> | <br>**Total** |
| Domestic Total (United States & Canada) | 274 | 6 | 136 | 416 |
| International: |  |  |  |  |
| &nbsp;&nbsp;Greater China | 385 | 101 | 307 | 793 |
| &nbsp;&nbsp;Asia (excluding Greater China) | 52 | 1 | 133 | 186 |
| &nbsp;&nbsp;Western Europe | 45 | 13 | 78 | 136 |
| &nbsp;&nbsp;Latin America | 4 |  | 58 | 62 |
| &nbsp;&nbsp;Rest of the World | 12 |  | 133 | 145 |
| &nbsp;&nbsp;&nbsp;&nbsp;International Total | 498 | 115 | 709 | 1322 |
| Worldwide Total<sup>(2)</sup> | 772 | 121 | 845 | 1738 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Period-to-period changes in the tables above are reported net of permanently closed systems.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Period-to-period changes in the tables above are reported net of permanently closed systems.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Period-to-period changes in the tables above are reported net of permanently closed systems.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Period-to-period changes in the tables above are reported net of permanently closed systems.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Period-to-period changes in the tables above are reported net of permanently closed systems.* |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

*Backlog*

The following tables provide detailed information about the Company's backlog by arrangement type and geographic location as of March 31, 2026 and 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| | **IMAX System Backlog** | **IMAX System Backlog** | **IMAX System Backlog** | **IMAX System Backlog** |
| | **Traditional**<br>**JRSA** | **Hybrid**<br>**JRSA** | **Sales** <br>**Arrangements**<sup>(1)</sup> | <br>**Total** |
| Domestic Total (United States & Canada) | 90 | 2 | 25 | 117 |
| International: |  |  |  |  |
| &nbsp;&nbsp;Greater China | 85 | 59 | 74 | 218 |
| &nbsp;&nbsp;Asia (excluding Greater China) | 14 |  | 30 | 44 |
| &nbsp;&nbsp;Western Europe | 4 |  | 9 | 13 |
| &nbsp;&nbsp;Latin America |  |  | 6 | 6 |
| &nbsp;&nbsp;Rest of the World | 1 |  | 36 | 37 |
| &nbsp;&nbsp;&nbsp;&nbsp;International Total | 104 | 59 | 155 | 318 |
| Worldwide Total<sup>(2)(3)</sup> | 194 | 61 | 180 | 435 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Worldwide Total of 435 includes 219 new IMAX Laser Systems and 134 upgrades of existing locations to IMAX Laser Systems.*<br>*(3)Worldwide Total of 435 includes 301 new systems and 134 upgrades.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Worldwide Total of 435 includes 219 new IMAX Laser Systems and 134 upgrades of existing locations to IMAX Laser Systems.*<br>*(3)Worldwide Total of 435 includes 301 new systems and 134 upgrades.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Worldwide Total of 435 includes 219 new IMAX Laser Systems and 134 upgrades of existing locations to IMAX Laser Systems.*<br>*(3)Worldwide Total of 435 includes 301 new systems and 134 upgrades.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Worldwide Total of 435 includes 219 new IMAX Laser Systems and 134 upgrades of existing locations to IMAX Laser Systems.*<br>*(3)Worldwide Total of 435 includes 301 new systems and 134 upgrades.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Worldwide Total of 435 includes 219 new IMAX Laser Systems and 134 upgrades of existing locations to IMAX Laser Systems.*<br>*(3)Worldwide Total of 435 includes 301 new systems and 134 upgrades.* |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** |
| | **IMAX System Backlog** | **IMAX System Backlog** | **IMAX System Backlog** | **IMAX System Backlog** |
| | **Traditional**<br>**JRSA** | **Hybrid**<br>**JRSA** | **Sales** <br>**Arrangements**<sup>(1)</sup> | <br>**Total** |
| Domestic Total (United States & Canada) | 122 | 2 | 11 | 135 |
| International: |  |  |  |  |
| &nbsp;&nbsp;Greater China | 95 | 90 | 49 | 234 |
| &nbsp;&nbsp;Asia (excluding Greater China) | 20 | 2 | 39 | 61 |
| &nbsp;&nbsp;Western Europe | 12 |  | 23 | 35 |
| &nbsp;&nbsp;Latin America | 1 |  | 7 | 8 |
| &nbsp;&nbsp;Rest of the World | 2 |  | 41 | 43 |
| &nbsp;&nbsp;&nbsp;&nbsp;International Total | 130 | 92 | 159 | 381 |
| Worldwide Total<sup>(2)(3)</sup> | 252 | 94 | 170 | 516 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Worldwide Total of 516 includes 254 new IMAX Laser Systems and 161 upgrades of existing locations to IMAX Laser Systems.*<br>*(3)Worldwide Total of 516 includes 355 new systems and 161 upgrades.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Worldwide Total of 516 includes 254 new IMAX Laser Systems and 161 upgrades of existing locations to IMAX Laser Systems.*<br>*(3)Worldwide Total of 516 includes 355 new systems and 161 upgrades.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Worldwide Total of 516 includes 254 new IMAX Laser Systems and 161 upgrades of existing locations to IMAX Laser Systems.*<br>*(3)Worldwide Total of 516 includes 355 new systems and 161 upgrades.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Worldwide Total of 516 includes 254 new IMAX Laser Systems and 161 upgrades of existing locations to IMAX Laser Systems.*<br>*(3)Worldwide Total of 516 includes 355 new systems and 161 upgrades.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Worldwide Total of 516 includes 254 new IMAX Laser Systems and 161 upgrades of existing locations to IMAX Laser Systems.*<br>*(3)Worldwide Total of 516 includes 355 new systems and 161 upgrades.* |

---

The backlog reflects the minimum number of commitments for IMAX Systems according to signed contracts. The Company believes that the contractual obligations for IMAX System installations that are listed in backlog are valid and binding commitments. From time to time, the Company and its customers may amend the arrangement type of a backlog system, and in the normal course of its business the Company will have customers who are unable to proceed with an IMAX System installation for a variety of reasons, including the inability to obtain certain consents, approvals or financing.

Certain of the Company's contracts contain options for the customer to elect to upgrade system type during the term or to alter the contract structure (for example, from a JRSA to a sale) after signing, but before installation. Current backlog information reflects all known elections.

As of March 31, 2026, 73% of IMAX System arrangements in backlog were scheduled to be installed in international markets (2025 — 74%).

(See "Risk Factors – The Company may not convert all of its backlog into revenue and cash flows." in Part I, Item 1A of the Company's 2025 Form 10-K.)

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

*Signings and Installations*

The following tables provide detailed information about IMAX System signings and installations for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| | **2026** | **2025** |
| System Signings: |  |  |
| &nbsp;&nbsp;Sales Arrangements<sup>(1)</sup> | 21 | 19 |
| &nbsp;&nbsp;Traditional JRSA<sup>(2)</sup> | 2 | 76 |
| Total IMAX System signings<sup>(3)</sup> | 23 | 95 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Includes 70 Traditional JRSA IMAX System signings with AMC Entertainment in 2025.*<br>*(3)Includes IMAX System upgrades of 13 for the three months ended March 31, 2026 (2025 ― 58 upgrades).* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Includes 70 Traditional JRSA IMAX System signings with AMC Entertainment in 2025.*<br>*(3)Includes IMAX System upgrades of 13 for the three months ended March 31, 2026 (2025 ― 58 upgrades).* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Includes Sales and Sales-Type Lease deal types.*<br>*(2)Includes 70 Traditional JRSA IMAX System signings with AMC Entertainment in 2025.*<br>*(3)Includes IMAX System upgrades of 13 for the three months ended March 31, 2026 (2025 ― 58 upgrades).* |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| | **2026** | **2025** |
| System Installations<sup>(1)</sup>: |  |  |
| &nbsp;&nbsp;Sales Arrangements<sup>(2)</sup> | 8 | 13 |
| &nbsp;&nbsp;Traditional JRSA | 11 | 8 |
| Total IMAX System installations<sup>(3)</sup> | 19 | 21 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)No IMAX Systems were relocated from their original location for the three months ended March 31, 2026 (2025 ― three). When a system is relocated, the amount of revenue earned by the Company may vary from transaction-to-transaction and is usually less than the amount earned for a new sale. In certain situations when a system is relocated, the original location is upgraded to an IMAX Laser System.*<br>*(2)Includes Sales and Sales-Type Lease deal types.*<br>*(3)Includes 11 IMAX System upgrades for the three months ended March 31, 2026 (2025 ― seven upgrades).* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)No IMAX Systems were relocated from their original location for the three months ended March 31, 2026 (2025 ― three). When a system is relocated, the amount of revenue earned by the Company may vary from transaction-to-transaction and is usually less than the amount earned for a new sale. In certain situations when a system is relocated, the original location is upgraded to an IMAX Laser System.*<br>*(2)Includes Sales and Sales-Type Lease deal types.*<br>*(3)Includes 11 IMAX System upgrades for the three months ended March 31, 2026 (2025 ― seven upgrades).* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)No IMAX Systems were relocated from their original location for the three months ended March 31, 2026 (2025 ― three). When a system is relocated, the amount of revenue earned by the Company may vary from transaction-to-transaction and is usually less than the amount earned for a new sale. In certain situations when a system is relocated, the original location is upgraded to an IMAX Laser System.*<br>*(2)Includes Sales and Sales-Type Lease deal types.*<br>*(3)Includes 11 IMAX System upgrades for the three months ended March 31, 2026 (2025 ― seven upgrades).* |

---

**RESULTS OF OPERATIONS**

The Company's results for the first quarter reflect variability driven by the timing, mix and geographic distribution of global box office performance. The year-over-year decline in total global box office was primarily attributable to an unusually strong prior-year comparison in Greater China. Domestic and other international markets experienced strong box office growth, driven by the performance of Hollywood titles and Filmed For IMAX releases. The Company's future results may continue to be affected by the timing and performance of major film releases, the mix of Hollywood and local language content, and the geographic concentration of box office revenues, as well as by variability in system installations and box office-driven revenues. In addition, broader macroeconomic conditions, including global economic uncertainty, supply chain disruptions, inflationary pressures and geopolitical tensions and conflicts, could adversely impact consumer demand and the Company's ability to deliver and install IMAX systems, any of which could materially affect the Company's financial condition and results of operations.

**Results of Operations for the Three Months Ended March 31, 2026 and 2025** 

***Net Income and Adjusted Net Income Attributable to Common Shareholders***

The following table presents the Company's net income attributable to common shareholders and the associated per diluted share amounts, as well as adjusted net income attributable to common shareholders\* and adjusted net income attributable to common shareholders per diluted share for the three months ended March 31, 2026 and 2025:

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| <br>*(In thousands of U.S. Dollars, except per diluted share amounts)* | **Net Income** | **Per Diluted Share** | **Net Income** | **Per Diluted Share** |
| Net income attributable to common shareholders | $4226 | $0.07 | $2327 | $0.04 |
| Adjusted net income attributable to common shareholders\* | $9568 | $0.17 | $7178 | $0.13 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*\*Refer to "Non-GAAP Financial Measures" for a description of this non-GAAP financial measure and a reconciliation to the most comparable GAAP amount.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*\*Refer to "Non-GAAP Financial Measures" for a description of this non-GAAP financial measure and a reconciliation to the most comparable GAAP amount.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*\*Refer to "Non-GAAP Financial Measures" for a description of this non-GAAP financial measure and a reconciliation to the most comparable GAAP amount.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*\*Refer to "Non-GAAP Financial Measures" for a description of this non-GAAP financial measure and a reconciliation to the most comparable GAAP amount.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*\*Refer to "Non-GAAP Financial Measures" for a description of this non-GAAP financial measure and a reconciliation to the most comparable GAAP amount.* |

---

***Revenues and Gross Margin***

For the three months ended March 31, 2026, the Company's revenues and gross margin were $81.4 million and $45.8 million, respectively. In comparison to the prior year first quarter, the Company's revenues and gross margin decreased by $5.3 million, or 6%, and $7.4 million, or 14%, respectively, principally due to lower IMAX box office performance in Greater China, which more than offset the growth in the domestic and other international markets.

The following table presents the Company's revenue, gross margin, and gross margin percentage by reportable segment for the three months ended March 31, 2026 and 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Revenue** | **Revenue** | **Gross Margin** | **Gross Margin** | **Gross Margin %** | **Gross Margin %** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** | **2026** | **2025** | **2026** | **2025** |
| &nbsp;&nbsp;Content Solutions | $31370 | $34249 | $18320 | $23554 | 58% | 69% |
| &nbsp;&nbsp;Technology Products and Services | 48338 | 50593 | 26882 | 29086 | 56% | 57% |
| &nbsp;&nbsp;&nbsp;&nbsp;Sub-total for reportable segments | 79708 | 84842 | 45202 | 52640 | 57% | 62% |
| &nbsp;&nbsp;All Other<sup>(1)</sup> | 1671 | 1825 | 609 | 536 | 36% | 29% |
| Total | $81379 | $86667 | $45811 | $53176 | 56% | 61% |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)All Other includes the results from Streaming and Consumer Technology and other ancillary activities.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)All Other includes the results from Streaming and Consumer Technology and other ancillary activities.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)All Other includes the results from Streaming and Consumer Technology and other ancillary activities.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)All Other includes the results from Streaming and Consumer Technology and other ancillary activities.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)All Other includes the results from Streaming and Consumer Technology and other ancillary activities.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)All Other includes the results from Streaming and Consumer Technology and other ancillary activities.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)All Other includes the results from Streaming and Consumer Technology and other ancillary activities.* |

---

***Content Solutions***

For the three months ended March 31, 2026, Content Solutions segment revenues and gross margin decreased by $2.9 million, or 8%, and by $5.2 million, or 22%, respectively, when compared to the same period in 2025.

In the three months ended March 31, 2026, box office generated by IMAX films totaled $259.6 million, a $38.5 million, or 13%, decrease versus the prior year comparative period of $298.2 million. This decrease was primarily driven by lower local language box office in the first quarter of 2026, due partially to the shift in 2026 local language blockbuster films from the Chinese New Year period to later in the year versus a record Chinese New Year in the first quarter of 2025 from the breakout performance of *Ne Zha 2* (the highest grossing local language film of all time). Domestic and international (excluding Greater China) global box office increased 75% and 60%, respectively, over the prior year comparative period as the performance of Hollywood content strengthened. During the three months ended March 31, 2026, IMAX box office was generated by the exhibition of 34 films and other content (31 new films, two re-releases, and one carry-over), including the following Hollywood titles: *Avatar: Fire and Ash* ($77 million), *Project Hail Mary* ($66 million), *Scream 7* ($8 million), and *Wuthering Heights* ($7 million). In addition, in the three months ended March 31, 2026, local language films exhibited across the Company's global network generated $62 million in box office, representing 24% of its global box office, including the Chinese local language film, *Pegasus 3* ($34 million) and *Blades of the Guardians* ($7 million). In the three months ended March 31, 2025, IMAX box office revenue was generated by the exhibition of 34 films (33 new films and one re-release), with Chinese local language film *Ne Zha 2* representing 54% of its global box office.

In the three months ended March 31, 2026, the Company released four movies that were filmed with IMAX proprietary cameras (Filmed For IMAX), including *Mercy*, *The Bride!*, *Project Hail Mary*, and the IMAX documentary *Athos.* Filmed For IMAX movies historically have performed disproportionately well at the box office, and for three of these films, IMAX delivered approximately 20% or more of the opening weekend domestic box office, despite accounting for only 1% of available screens.

In addition to the level of revenues, Content Solutions segment gross margin is influenced by the costs associated with films and other content exhibited in the period. These costs can include production, post-production, distribution, and marketing, which are expensed as incurred. For the three months ended March 31, 2026, gross margin percent was 58% compared to 69% in the prior period. The Content Solutions margin decline was driven by a combination of factors including; lower box office performance in Greater China, with no significant breakout title, a lower mix of local language films which carries a higher margin, and an increased level of film marketing spend associated with upcoming large tentpole titles.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

***Technology Products and Services***

The following table provides information about IMAX Systems installed and the associated revenue recognized at that time, except for traditional JRSAs, for which revenue is recognized over the lease term, during the three months ended March 31, 2026 and 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| *(In thousands of U.S. Dollars, except number of systems)* | **Number of <br>Systems** | **Revenue** | **Number of <br>Systems** | **Revenue** |
| New IMAX Systems | 6 | $4730 | 12 | $9124 |
| Upgraded IMAX Systems | 2 | 2551 | 1 | 1460 |
| Total | 8 | $7281 | 13 | $10584 |

---

In the three months ended March 31, 2026, no IMAX Systems were relocated from their original locations (2025 ― three IMAX Systems). When a system under a sale or sales-type lease arrangement is relocated, the amount of revenue earned by the Company may vary from transaction to transaction and is usually less than the amount earned for a new sale. In certain situations when a system is relocated, the original location is upgraded to an IMAX Laser System.

For the three months ended March 31, 2026, Technology Products and Services segment revenue and gross margin decreased by $2.3 million, or 4%, and $2.2 million, or 8%, respectively, when compared to the same period in the prior year. The lower level of revenue was primarily driven by a lower level of rental revenues, which are box office dependent. Rental revenues of $16.6 million, a decrease of $2.6 million from $19.1 million in the prior year comparative period, were driven by a $31.8 million decrease in GBO from JRSAs in the three months ended March 31, 2026 versus the prior year. Specifically, in the first quarter of 2026 an increase of $5.3 million in rental revenues from domestic and international markets (excluding Greater China) was more than offset by a $7.9 million revenue decline in Greater China. Also contributing to the decrease in the segment revenue was the lower number of systems recognized under sales and sales-type lease arrangements, per the table above.

The decreases in revenue were partially offset by a $3.1 million increase in revenue contribution from the impact of amendments, renewals and other adjustments to existing IMAX Systems arrangements.

For the three months ended March 31, 2026, gross margin percent was 56% compared to 57% in the same period in the prior year, which primarily reflects the lower level of rental revenues offset partially by the impact of amendments, renewals and other adjustments as described above, which did not have associated costs.

***All Other***

For the three months ended March 31, 2026, All Other revenue and gross margin decreased by $0.2 million, and less than $0.1 million, respectively, when compared to the same period in 2025, which principally reflects the results of the Company's SCT business which was re-positioned and relaunched in late 2025 under the brand of IMAX Enhanced.

***Selling, General and Administrative Expenses***

The following table presents information about the Company's Selling, General and Administrative Expenses for the three months ended March 31, 2026 and 2025:

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | |
| | **March 31,** | **March 31,** | **Variance** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** | $**%** |
| Total Selling, general and administrative expenses | $32488 | $33462 | (3%) |
| Less: Share-based compensation<sup>(1)</sup> | (5909) | (4720) | (25%) |
| Total selling, general and administrative expenses, excluding share-based compensation<sup>(2)</sup> | $26579 | $28742 | (8%) |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)A portion of share-based compensation expense is recognized within Cost and Expenses Applicable to Revenue, and Research and Development. (Refer to "Capital Stock and Reserves — Share-Based Compensation" in Note 11 of Notes to Condensed Consolidated Financial Statements in Part I, Item 1.)*<br>*(2)See "Non-GAAP Financial Measures" for a description of this non-GAAP financial measure and a reconciliation to the most comparable GAAP amount.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)A portion of share-based compensation expense is recognized within Cost and Expenses Applicable to Revenue, and Research and Development. (Refer to "Capital Stock and Reserves — Share-Based Compensation" in Note 11 of Notes to Condensed Consolidated Financial Statements in Part I, Item 1.)*<br>*(2)See "Non-GAAP Financial Measures" for a description of this non-GAAP financial measure and a reconciliation to the most comparable GAAP amount.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)A portion of share-based compensation expense is recognized within Cost and Expenses Applicable to Revenue, and Research and Development. (Refer to "Capital Stock and Reserves — Share-Based Compensation" in Note 11 of Notes to Condensed Consolidated Financial Statements in Part I, Item 1.)*<br>*(2)See "Non-GAAP Financial Measures" for a description of this non-GAAP financial measure and a reconciliation to the most comparable GAAP amount.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)A portion of share-based compensation expense is recognized within Cost and Expenses Applicable to Revenue, and Research and Development. (Refer to "Capital Stock and Reserves — Share-Based Compensation" in Note 11 of Notes to Condensed Consolidated Financial Statements in Part I, Item 1.)*<br>*(2)See "Non-GAAP Financial Measures" for a description of this non-GAAP financial measure and a reconciliation to the most comparable GAAP amount.* |

---

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

Selling, General and Administrative Expenses decreased period over period, reflecting management's continued focus on operational efficiencies, including the impact of prior workforce reductions, timing and other cost discipline initiatives.

***Research and Development***

For the three months ended March 31, 2026, Research and Development expenses were $1.8 million, representing an increase of $0.5 million, or 37%, when compared to Research and Development expenses of $1.3 million during the same period in the prior year. The increase year-over-year was primarily driven by the capitalization of film camera costs in 2025 in accordance with the achievement of technological feasibility in 2024. The Company continues to expense its investment in other projects, including in the development of new product offerings and improvements to its existing IMAX System product suite.

***Credit Loss Reversal, Net***

For the three months ended March 31, 2026, the Company recorded a credit loss reversal of $0.5 million, as compared to $0.1 million recognized in the same period of the prior year.

Overall, continued strong global box office performance has contributed to a notable improvement in collections. Strong theatrical attendance, driven by a robust film slate, has increased and accelerated cash inflows from studio and exhibitor customers. This trend reflects the continued consumer demand for premium cinematic experiences and effectiveness of IMAX's strategic initiatives to partner with filmmakers, studios, and exhibitors to deliver higher levels of box office.

The Company estimates credit losses based on both a historical provision rate and customer specific circumstances. Management's judgments regarding expected credit losses are based on the facts available to management at the time that the Condensed Consolidated Financial Statements are prepared and involve estimates about the future. As a result, the Company's judgments and associated estimates of credit losses may ultimately prove, with the benefit of hindsight, to be incorrect. (Refer to Note 3 of Notes to Condensed Consolidated Financial Statements in Part I, Item 1).

***Interest Expense and Interest Income***

For the three months ended March 31, 2026, interest expense was $1.9 million, representing an increase of $0.1 million, or 5%, as compared to $1.8 million during the same period of the prior year primarily due to higher level of borrowings under the Credit Facility (as defined under "—Liquidity and Capital Resources" below), including $8.7 million paid for lease incentives provided to exhibitor customers, in the current period offset mostly by lower average interest rates. The effective interest rate for the three months ended March 31, 2026 was 5.19% (2025 — 6.18%). For each of the three months ended March 31, 2026 and 2025, interest income was $0.5 million.

***Income Taxes***

For the three months ended March 31, 2026, the Company recorded an income tax expense of $2.4 million (2025 — $7.3 million). The Company's effective tax rate of 28.5% for the three months ended March 31, 2026, reflects the geographic allocation of income earned in taxing jurisdictions and also reflects an increase in the valuation allowance, and withholding taxes, offset by a tax benefit related to share-based compensation. The Company's effective tax rate of 47.2% for the three months ended March 31, 2025, reflects the geographic allocation of income earned in taxing jurisdictions and also reflects an increase in the valuation allowance, withholding taxes and a tax benefit related to share-based compensation.

***Non-Controlling Interests***

For the three months ended March 31, 2026, the net income attributable to non-controlling interests of the Company's subsidiaries was $1.8 million, a decrease of $4.0 million, when compared to the same period in 2025, which reflects a $19.6 million total revenue decline primarily driven by the lower level of IMAX box office earned in Greater China.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**

The discussion below summarizes our cash flows from operating, investing, and financing activities as reflected in the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Net cash provided by (used in) |  |  |
| &nbsp;&nbsp;Operating activities | $4029 | $6951 |
| &nbsp;&nbsp;Investing activities | (6927) | (14624) |
| &nbsp;&nbsp;Financing activities | (2762) | 4234 |
| Effect of exchange rate changes on cash | 487 | (84) |
| Net change in cash | $**(5173)** | $**(3523)** |

---

Net cash provided by the Company's operating activities decreased $2.9 million in the three months ended March 31, 2026, when compared to the same period in 2025, primarily driven by a $7.7 million increase in cash payments related to lease incentives provided to exhibitor customers and annual short term incentive compensation payouts. This higher level of cash outflow was partially offset by strong Accounts Receivable collections during the period. (Refer to Note 9 to Condensed Consolidated Financial Statements in Item 1. for more information on the Company's change in other operating assets and liabilities.)

Net cash used in investing activities decreased $7.7 million in the three months ended March 31, 2026, when compared to the same period in 2025. Cash used in the investment in equipment contributed to the Company's JRSAs with exhibitor customers was higher in the first quarter of 2025 due in part to the Company shipping systems into the U.S. in advance of planned 2025 system installations as a proactive measure in response to new and potentially changing tariffs. (Refer to "Risk Factors—The Company's business may be materially adversely affected by the imposition of tariffs and other trade barriers and retaliatory countermeasures implemented by the United States and other governments." in Part I, Item 1A. in the 2025 Form 10-K.)

Net cash used in financing activities decreased $7.0 million in the three months ended March 31, 2026, when compared to the same period in 2025, mainly driven by higher taxes withheld and paid on employee stock awards vested due to the Company's higher stock price relative to grant dates, and outperformance of PSUs vested during the period. This decrease was partially offset by cash received for stock options exercised during the period.

**LIQUIDITY AND CAPITAL RESOURCES** 

As of March 31, 2026, the Company's principal sources of liquidity included: (i) its balances of cash and cash equivalents of $146.0 million; (ii) the anticipated collection of trade accounts receivable, which includes amounts owed under JRSAs and Film Remastering and distribution agreements with movie studios; (iii) the anticipated collection of financing and variable consideration receivables due in the next 12 months under sale and sales-type lease arrangements for systems currently in operation; and (iv) installment payments expected in the next 12 months under sale and sales-type lease arrangements in backlog. Under the terms of the Company's typical sale and sales-type lease agreements, the Company receives substantial cash payments before it completes the performance of its contractual obligations.

In addition, as of March 31, 2026, the Company had $326.0 million in available borrowing capacity under its Credit Facility pursuant to its Seventh Amended and Restated Credit Agreement (the "Credit Agreement"), $27.5 million in available borrowing capacity under the IMAX Shanghai revolving credit facility with the Bank of China (the "Bank of China Facility"), and $28.9 million in available borrowing capacity under IMAX Shanghai's revolving credit facility with HSBC Bank (China) Company Limited, Shanghai Branch (the "HSBC China Facility"). Refer to "Borrowings — Convertible Notes and Other Borrowings, Net" in Note 6 of Notes to Condensed Consolidated Financial Statements in Part I, Item 1.

The Company's $146.0 million balance of cash and cash equivalents as of March 31, 2026 (December 31, 2025 — $151.2 million) included $139.5 million in cash held outside of Canada (December 31, 2025 — $137.4 million), of which $101.0 million was held in the People's Republic of China (the "PRC") (December 31, 2025 — $97.2 million). Management reassessed its strategy with respect to the most efficient means of deploying the Company's capital resources globally and determined that historical earnings of certain foreign subsidiaries in excess of amounts required to sustain business operations would no longer be indefinitely reinvested. During the three months ended March 31, 2026, no historical earnings from a subsidiary in the PRC were distributed (2025 — $nil) and, as a result, no foreign withholding taxes were paid to the relevant tax authorities (2025 — $nil). As of March 31, 2026, the Company's Condensed Consolidated Balance Sheets included a deferred tax liability of $12.5 million for the applicable foreign withholding taxes

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

associated with the remaining balance of non-repatriated historical earnings that will not be indefinitely reinvested outside of Canada. These taxes will become payable upon the repatriation of any such earnings.

The Company forecasts its future cash flow and short-term liquidity requirements on an ongoing basis. These forecasts are based on estimates and may be materially impacted by factors that are outside of the Company's control (including the factors described in "Risk Factors" in Part I, Item 1A of the Company's 2025 Form 10-K as supplemented by "Risk Factors" in Part II, Item 1A of this Form 10-Q). As a result, there is no guarantee that these forecasts will come to fruition and that the Company will be able to fund its operations through cash flows from operations. In particular, the Company's operating cash flows and cash balances will be adversely impacted if management's projections of future signings and installations of IMAX Systems and box office performance of IMAX content are not realized.

The Company also has certain significant contractual obligations and commitments that have been disclosed in "Contractual Obligations" in Part II, Item 7 of the Company's 2025 Form 10-K. There are no material changes to these obligations and commitments as of March 31, 2026.

Based on the Company's current cash balances and operating cash flows, management expects to have sufficient capital and liquidity to fund its anticipated operating needs and capital requirements during the next twelve-month period following the date of this report.

**OFF-BALANCE SHEET ARRANGEMENTS**

There are currently no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on the Company's financial condition.

**CRITICAL ACCOUNTING ESTIMATES**

The preparation of financial statements and related disclosures in accordance with U.S. GAAP requires management to make judgments, assumptions, and estimates that affect the amounts reported in the Company's Condensed Consolidated Financial Statements and accompanying notes. Management's judgments, assumptions, and estimates are based on historical experience, future expectations, and other factors that are believed to be reasonable as of the date of the Company's Condensed Consolidated Financial Statements. Actual results may ultimately differ from the Company's original estimates, as future events and circumstances sometimes do not develop as expected, and the differences may be material. For more information on the Company's critical accounting estimates refer to the section entitled "Critical Accounting Estimates" in Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" of the 2025 Form 10-K.

**RECENTLY ISSUED ACCOUNTING STANDARDS**

Refer to Note 2 of Notes to Condensed Consolidated Financial Statements in Part I, Item 1 for a discussion of recently issued accounting standards and their impact on the Company's Condensed Consolidated Financial Statements.

 **NON-GAAP FINANCIAL MEASURES**

GAAP refers to generally accepted accounting principles in the United States of America. In this report, the Company presents financial measures in accordance with GAAP and also on a non-GAAP basis under the U.S. Securities and Exchange Commission regulations. Specifically, the Company presents the following non-GAAP financial measures as supplemental measures of its performance:

&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income or loss attributable to common shareholders;

&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income or loss attributable to common shareholders per basic and diluted share;

&nbsp;&nbsp;&nbsp;&nbsp;• EBITDA;

&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA per Credit Facility; and

&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted SG&A expenses.

Adjusted net income or loss attributable to common shareholders and adjusted net income or loss attributable to common shareholders per basic and diluted share exclude, where applicable: (i) share-based compensation; (ii) realized and unrealized

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

investment gains or losses; (iii) goodwill impairment; (iv) restructuring charges and other impairments; (v) employee retention credits; and (vi) induced conversion expense on settlement of convertible notes, as well as the related tax impact of these adjustments.

The Company believes that these non-GAAP financial measures are important supplemental measures that allow management and users of the Company's financial statements to view operating trends and analyze controllable operating performance on a comparable basis between periods without the after-tax impact of share-based compensation and certain unusual items included in net income attributable to common shareholders. Although share-based compensation is an important aspect of the Company's employee and executive compensation packages, it is a non-cash expense and is excluded from certain internal business performance measures.

Reconciliations of net income attributable to common shareholders and the associated per share amounts to adjusted net income attributable to common shareholders and adjusted net income attributable to common shareholders per diluted share are presented in the tables below.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| *(In thousands of U.S. Dollars, except per diluted share amounts)* | **Net Income** | **Per Diluted Share** | **Net Income** | **Per Diluted Share** |
| Net income attributable to common shareholders | $4226 | $0.07 | $2327 | $0.04 |
| Adjustments<sup>(1)</sup>: |  |  |  |  |
| &nbsp;&nbsp;Share-based compensation | 5807 | 0.11 | 5212 | 0.10 |
| &nbsp;&nbsp;Unrealized investment gains | (36) |  | (32) |  |
| &nbsp;&nbsp;Restructuring charges and other impairments |  |  | 57 |  |
| &nbsp;&nbsp;Tax impact on items listed above | (429) | (0.01) | (386) | (0.01) |
| Adjusted net income<sup>(1)</sup> | $9568 | $0.17 | $7178 | $0.13 |
| Weighted average shares outstanding — basic |  | 54125 |  | 53145 |
| Weighted average shares outstanding — diluted |  | 56392 |  | 54969 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Reflects amounts attributable to common shareholders.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Reflects amounts attributable to common shareholders.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Reflects amounts attributable to common shareholders.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Reflects amounts attributable to common shareholders.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)Reflects amounts attributable to common shareholders.* |

---

In addition to the non-GAAP financial measures discussed above, management also uses "EBITDA," as such term is defined in the Credit Agreement, and which is referred to herein as "Adjusted EBITDA per Credit Facility." As defined in the Credit Agreement, Adjusted EBITDA per Credit Facility includes adjustments in addition to the exclusion of interest, taxes, depreciation and amortization. Accordingly, this non-GAAP financial measure is presented to allow a more comprehensive analysis of the Company's operating performance and to provide additional information with respect to the Company's compliance with its Credit Agreement requirements, when applicable. In addition, the Company believes that Adjusted EBITDA per Credit Facility presents relevant and useful information widely used by analysts, investors and other interested parties in the Company's industry to evaluate, assess and benchmark the Company's results.

EBITDA is defined as net income or loss excluding: (i) income tax expense or benefit; (ii) interest expense, net of interest income; (iii) depreciation and amortization, including film asset amortization; and (iv) amortization of deferred financing costs. Total Adjusted EBITDA per Credit Facility is defined as EBITDA excluding: (i) share-based and other non-cash compensation; (ii) realized and unrealized investment gains or losses; (iii) restructuring charges and other impairments; (iv) write-downs, net of recoveries, including goodwill, asset impairments and credit loss expense or reversal; and (v) induced conversion expense on settlement of convertible notes.

Reconciliations of net income attributable to common shareholders, which is the most directly comparable GAAP measure, to EBITDA and Adjusted EBITDA per Credit Facility are presented in the tables below:

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

---

| | |
|:---|:---|
| *(In thousands of U.S. Dollars)* | **Three Months Ended March 31, 2026** |
| Net income | $6071 |
| Add (subtract): |  |
| &nbsp;&nbsp;Income tax expense | 2421 |
| &nbsp;&nbsp;Interest expense, net of interest income | 900 |
| &nbsp;&nbsp;Depreciation and amortization, including film asset amortization | 15236 |
| &nbsp;&nbsp;Amortization of deferred financing costs<sup>(1)</sup> | 528 |
| &nbsp;&nbsp;EBITDA | 25156 |
| &nbsp;&nbsp;Share-based and other non-cash compensation | 5792 |
| &nbsp;&nbsp;Unrealized investment gains | (36) |
| &nbsp;&nbsp;Write-downs, including asset impairments and credit loss expense | (403) |
| Total Adjusted EBITDA | $30509 |
| Less: Non-controlling interest | (3700) |
| Adjusted EBITDA per Credit Facility - attributable to common shareholders | $26809 |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The amortization of deferred financing costs is recorded within Interest Expense in the Condensed Consolidated Statements of Operations.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The amortization of deferred financing costs is recorded within Interest Expense in the Condensed Consolidated Statements of Operations.* |

---

---

| | |
|:---|:---|
| *(In thousands of U.S. Dollars)* | **Twelve Months Ended March 31, 2026** |
| Net income | $43447 |
| Add (subtract): |  |
| &nbsp;&nbsp;Income tax expense | 12903 |
| &nbsp;&nbsp;Interest expense, net of interest income | 2708 |
| &nbsp;&nbsp;Depreciation and amortization, including film asset amortization | 62769 |
| &nbsp;&nbsp;Amortization of deferred financing costs<sup>(1)</sup> | 2020 |
| &nbsp;&nbsp;&nbsp;&nbsp;EBITDA | 123847 |
| &nbsp;&nbsp;Share-based and other non-cash compensation | 27342 |
| &nbsp;&nbsp;Unrealized investment losses | 863 |
| &nbsp;&nbsp;Restructuring charges and other impairments | 2421 |
| &nbsp;&nbsp;Write-downs, including goodwill, asset impairments and credit loss expense | 8742 |
| &nbsp;&nbsp; Induced conversion expense on settlement of convertible notes | 15264 |
| Total Adjusted EBITDA | $178479 |
| Less: Non-controlling interest | (13967) |
| Adjusted EBITDA per Credit Facility - attributable to common shareholders | $164512 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The amortization of deferred financing costs is recorded within Interest Expense in the Condensed Consolidated Statements of Operations.* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)The amortization of deferred financing costs is recorded within Interest Expense in the Condensed Consolidated Statements of Operations.* |

---

The Company also adjusts SG&A Expenses to exclude a portion of share-based compensation and related payroll taxes. Management uses non-GAAP and other financial measures such as this, internally for financial and operational decision-making and as a means to evaluate period-to-period comparisons. IMAX believes that this non-GAAP measure provides useful information about operating results, enhances the overall understanding of past financial performance and future prospects, and allows for greater transparency with respect to key metrics used by management and its financial and operational decision making.

A reconciliation of Selling, General and Administrative Expenses, the most directly comparable GAAP measure presented in the Condensed Consolidated Statement of Operations in Part I, Item 1, to Adjusted Selling, General and Administrative Expenses is presented in the table below.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31,** | **March 31,** |
| *(In thousands of U.S. Dollars)* | **2026** | **2025** |
| Total Selling, general and administrative expenses | $32488 | $33462 |
| Less: Share-based compensation | (5909) | (4720) |
| Total Adjusted Selling, general and administrative expenses | $26579 | $28742 |

---

The Company cautions users of its financial statements that these non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies. Additionally, the non-GAAP financial measures used by the Company should not be considered in isolation, or as a substitute for, or superior to, the comparable GAAP amounts.

**Item 3.&nbsp;&nbsp;&nbsp;&nbsp;*Quantitative and Qualitative Disclosures about Market Risk***

The Company is exposed to market risk from foreign currency exchange rates and interest rates, which could affect operating results, financial position and cash flows. Market risk is the potential change in an instrument's value caused by, for example, fluctuations in interest and currency exchange rates. The Company's primary market risk exposure is the risk of unfavorable movements in exchange rates between the U.S. Dollar, the Canadian Dollar, and Chinese Renminbi ("RMB"). The Company does not use financial instruments for trading or other speculative purposes.

**Foreign Exchange Rate Risk**

A majority of the Company's revenue is denominated in U.S. Dollars while a significant portion of its costs and expenses is denominated in Canadian Dollars. A portion of the Company's net U.S. Dollar cash flows is converted to Canadian Dollars to fund Canadian Dollar expenses through the spot market. In addition, IMAX films generate box office in 91 different countries, and therefore unfavorable exchange rates between applicable local currencies and the U.S. Dollar could have an impact on the GBO generated by the Company's exhibitor customers and its revenues. The Company has incoming cash flows from its revenue generating IMAX network and ongoing operating expenses in China through its majority-owned subsidiary IMAX Shanghai. In Japan, the Company has ongoing Yen-denominated operating expenses related to its Japanese operations. Net RMB and Japanese Yen cash flows are converted to U.S. Dollars through the spot market. The Company also has cash receipts under leases denominated in RMB, Japanese Yen, British Pound Sterling, Euros and Canadian Dollars.

The Company manages its exposure to foreign exchange rate risks through its regular operating and financing activities and, when appropriate, through the use of derivative financial instruments. These derivative financial instruments are utilized to hedge economic exposures as well as reduce earnings and cash flow volatility resulting from shifts in market rates.

Certain of the Company's PRC subsidiaries held approximately RMB 690.7 million ($99.8 million) in cash and cash equivalents as of March 31, 2026 (December 31, 2025 — RMB 678.2 million or $96.5 million) and are required to transact locally in RMB. Foreign currency exchange transactions, including the remittance of any funds into and out of the PRC, are subject to controls and require the approval of the China State Administration of Foreign Exchange to complete. Any developments relating to the Chinese economy and any actions taken by the Chinese government are beyond the control of the Company; however, the Company monitors and manages its capital and liquidity requirements to ensure compliance with local regulatory and policy requirements. (Refer to "Risk Factors – The Company faces risks in connection with its significant presence in China and the continued expansion of its business there" in Part I, Item 1A. of the Company's 2025 Form 10-K.)

Management also monitors the macroeconomic environment as part of its continuous assessment of credit risk. This includes consideration of developments in the U.S. and global banking sectors, which informs management's assessment of any potential direct and indirect impacts on the Company. There are no concentrations of cash and cash equivalents in any regional banking institutions, such that management considers there to be any material risk in this regard.

For the three months ended March 31, 2026, the Company recorded a foreign exchange net loss of $0.6 million, resulting from changes in exchange rates related to foreign currency denominated monetary assets and liabilities (2025 — net loss of $0.4 million).

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

The Company has entered into a series of foreign currency forward contracts to manage the risks associated with the volatility of foreign currencies. Certain of these foreign currency forward contracts met the criteria required for hedge accounting under the Derivatives and Hedging Topic of the FASB ASC at inception, and continue to meet hedge effectiveness tests as of March 31, 2026, with settlement dates throughout 2026 and 2027. Foreign currency derivatives are recognized and measured on the Condensed Consolidated Balance Sheets at fair value. Changes in the fair value (i.e., gains or losses) are recognized in the Condensed Consolidated Statements of Operations except for derivatives designated and qualifying as foreign currency cash flow hedging instruments. The Company currently has cash flow hedging instruments associated with Selling, General and Administrative Expenses. For foreign currency cash flow hedging instruments related to Selling, General and Administrative Expenses, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported within Accumulated Other Comprehensive Income (Loss) and reclassified to the Condensed Consolidated Statements of Operations when the forecasted transaction occurs. Any ineffective portion is recognized immediately in the Condensed Consolidated Statements of Operations.

The notional value of foreign currency cash flow hedging instruments that qualify for hedge accounting as of March 31, 2026 was $38.5 million (December 31, 2025 — $48.4 million). Losses of $0.6 million was recorded to Other Comprehensive Income with respect to the change in fair value of these contracts for the three months ended March 31, 2026 (March 31, 2025 — losses of $0.7 million). Gains of $0.3 million were reclassified from Accumulated Other Comprehensive Income to Selling, General and Administrative Expenses for the three months ended March 31, 2026 (March 31, 2025 — losses of $1.3 million). The Company currently does not hold any derivatives which are not designated as hedging instruments.

For all derivative instruments, the Company is subject to counterparty credit risk to the extent that the counterparty may not meet its obligations to the Company. To manage this risk, the Company enters into derivative transactions only with major financial institutions.

As of March 31, 2026, the Company's Financing Receivables and working capital items denominated in Canadian Dollars, RMB, Japanese Yen, Euros and other foreign currencies translated into U.S. Dollars was $152.2 million. Assuming a 10% appreciation or depreciation in foreign currency exchange rates from the quoted foreign currency exchange rates as of March 31, 2026, the potential change in the fair value of foreign currency-denominated financing receivables and working capital items would have been $15.2 million. A significant portion of the Company's Selling, General, and Administrative Expenses is denominated in Canadian Dollars. Assuming a 1% change appreciation or depreciation in foreign currency exchange rates as of March 31, 2026, the potential change in the amount of Selling, General, and Administrative Expenses would be $0.1 million.

**Interest Rate Risk Management**

The Company's earnings may also be affected by changes in interest rates due to the impact those changes have on its interest income from cash, and its interest expense from variable-rate borrowings that may be made under the Credit Facility.

As of March 31, 2026, the Company had drawn down $49.0 million on its Credit Facility (December 31, 2025 — $37.0 million), and $nil on its HSBC China Facility (December 31, 2025 — $nil) and $nil on its Bank of China Facility (December 31, 2025 — $nil), which are subject to variable effective interest rates. If the interest rates available to the Company increased by 10%, the Company's interest expense would increase by $0.3 million and interest income from cash would increase by $0.3 million.

The Company had variable rate debt instruments representing 11% and 8% of its total liabilities as of March 31, 2026 and December 31, 2025, respectively. These amounts are determined by considering the impact of the hypothetical interest rates on the Company's variable rate debt and cash balances as of March 31, 2026.

**Item 4.&nbsp;&nbsp;&nbsp;&nbsp;*Controls and Procedures***

**EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES**

The Company maintains disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized, and reported within the specified time periods and that such information is accumulated and communicated to management, including the principal executive and principal financial officers, to allow timely discussions regarding required disclosure. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

The Company's management, with the participation of its principal executive and principal financial officers, has evaluated the effectiveness of the Company's "disclosure controls and procedures" (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) as of March 31, 2026 and has concluded that, as of the end of the period covered by this report, the Company's disclosure

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

controls and procedures were effective. The Company will continue to periodically evaluate its disclosure controls and procedures and will make modifications from time to time as deemed necessary to ensure that information is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms.

**CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING**

There were no changes in the Company's internal control over financial reporting which occurred during the three months ended March 31, 2026, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**PART II. OTHER INFORMATION**

**Item 1.&nbsp;&nbsp;&nbsp;&nbsp;*Legal Proceedings***

Refer to Note 7 of Notes to Condensed Consolidated Financial Statements in Part I, Item 1 for information regarding legal proceedings involving the Company.

**Item 1A. *Risk Factors***

This Form 10-Q should be read together with, and supplement, the risk factors in Item 1A "Risk Factors" in the Company's 2025 Form 10-K, which describes various risks and uncertainties to which the Company is or may become subject. The risk factors below update certain risk factors included in the Company's 2025 Form 10-K in light of recent events. The below risk factors and the risk factors included in the Company's 2025 Form 10-K are not the only risks facing the Company. Additional risks and uncertainties not currently known to the Company or that the Company currently deems to be immaterial also may materially adversely affect its business, financial condition and/or operating results.

***The Company conducts business internationally, which exposes it to uncertainties and risks that could negatively affect its operations, sales, and future growth prospects.***

A significant portion of the Company's revenues and of the GBO earned by the Company's exhibitor customers are generated outside the United States and Canada. Approximately 62%, 58%, and 64% of the Company's revenues were derived outside of the United States and Canada in 2025, 2024, and 2023, respectively. As of March 31, 2026, 73% of IMAX Systems in backlog were scheduled to be installed in international markets. The Company's network spanned 91 different countries as of March 31, 2026, and the Company expects its international operations to continue to account for an increasingly significant portion of its future revenues. There are a number of risks associated with operating in international markets that could negatively affect the Company's operations, sales and future growth prospects. These risks, among others, include:

<u>Operational and Supply Chain Risks</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• difficulties in obtaining competitively priced key commodities, raw materials, and component parts from various international sources that are needed to manufacture quality products on a timely basis;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• dependence on foreign distributors and their sales channels;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reliance on local partners in foreign territories, including in connection with JRSAs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• difficulties in staffing and managing foreign operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• inability to complete installations of IMAX Systems, including as a result of material disruptions or delays in the Company's supply chains, or to collect full payment on installations thereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• public health concerns, including pandemics or epidemics, and regulations in response thereto, which could adversely affect the Company's and its customers' operations; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• harm to the IMAX brand from operating in countries with records of controversial government action, including human rights abuses.

<u>Financial and Macroeconomic Risks</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fluctuations in the value of foreign currencies versus the U.S. Dollar, potential currency devaluations, and imposition of foreign exchange controls in foreign jurisdictions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• adverse changes in foreign government monetary and/or tax policies, and/or difficulties in repatriating cash from foreign jurisdictions (including with respect to China, where approval of the State Administration of Foreign Exchange is required);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• requirements to provide performance bonds and letters of credit to international customers to secure IMAX System component deliveries;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• less accurate and/or less reliable box office reporting;

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• difficulties in establishing market-appropriate pricing; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• economic conditions in foreign markets, including inflation.

<u>Geopolitical, Trade, and Regulatory Compliance Risks</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• new and potentially changing tariffs, trade protection measures, import or export licensing requirements, trade embargoes, sanctions and export controls, and other trade barriers, including but not limited to planned, implemented or threatened tariffs and retaliatory responses thereto, or the residual impacts and uncertainty as a result of changes in tariff or trade policy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• new restrictions on access to markets, both for IMAX Systems and content;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• unusual or burdensome foreign laws or regulatory requirements or unexpected changes to those laws or requirements, including censorship of content that may restrict what films or other content are exhibited across the Company's network;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• local business practices that can present challenges to compliance with applicable anti-corruption and bribery laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• poor recognition of intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• difficulties in enforcing contractual rights; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• war, conflict, geopolitical tensions and other political, economic and social instability, terrorist attacks and security concerns, such as the ongoing conflict between Russia and Ukraine, the war in Iran and other armed conflicts in the Middle East, and escalating tensions in the Taiwan Strait, all of which could result in adverse consequences for the Company's interests in different regions of the world.

Global geopolitical tensions and actions that governments take in response and the resulting global and regional economic downturns have had and may in the future adversely impact the Company's ability to operate in such regions. For example, the ongoing conflict between Russia and Ukraine and responses thereto have had and may continue to have an adverse impact on the Company's business and results of operations in affected regions, including the continued suspension of the Company's operations across the Company's 54 theaters in the region. Three theaters in Israel and one theater in Lebanon have been impacted by closures or are operating in limited capacity due to the Iran war. The other 31 of the Company's 35 theaters in the Middle East region remain fully operational. Furthermore, disruptions to key global shipping routes, including the Strait of Hormuz, have and may continue to adversely affect global supply chains by increasing transportation time and cost as well as increasing uncertainty in the availability of critical goods and services, which may in turn impact the Company's operations. Given the uncertainty as to the scope, intensity, duration and outcome of geopolitical conflicts, it is difficult to predict the full extent of the adverse impacts of geopolitical conflicts on the Company's business and results of operations. Additionally, given the global nature of the Company's operations, any protracted conflict or the broader macroeconomic impact of geopolitical conflicts and sanctions imposed in response thereto, have had and could continue to have an adverse impact on the Company's business, results of operations, financial condition, and future performance and may also magnify the impact of other risks described herein, including the risk of cybersecurity attacks, which may impact information technology systems unrelated to the conflict, or jeopardize critical infrastructure in jurisdictions where the Company operates.

While the Company has implemented policies, internal controls, and other measures reasonably designed to promote compliance with applicable laws and regulations related to doing business internationally, any violations of these laws and regulations, or even allegations of such a violation, could disrupt the Company's operations and harm the Company's business, financial condition and results of operations. In addition, changes in United States or Canadian foreign policy can present additional risks or uncertainties as the Company continues to expand its international operations. Opening and operating theaters in markets that have experienced geopolitical or sociopolitical unrest or controversy, including through partnerships with local entities, exposes the Company to the risks listed above, as well as additional risks of operating in a volatile region. Such risks may negatively impact the Company's business operations in such regions and may also harm the Company's brand. Moreover, a deterioration of the diplomatic relations between the United States or Canada and a particular country may impede the Company's ability to conduct business in that country and have a negative impact on the Company's financial condition and future growth prospects.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**Item 2.&nbsp;&nbsp;&nbsp;&nbsp;*Unregistered Sales of Equity Securities and Use of Proceeds***

**Issuer Purchases of Equity Securities**

On June 12, 2017, the Company announced that its Board of Directors approved a $200.0 million share repurchase program for its common shares that would have expired on June 30, 2020, which was subsequently extended through June 30, 2026 and increased in the total share repurchase authority to $500.0 million under the current share repurchase program. As of March 31, 2026, the Company had $250.7 million available under the program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant to a plan intended to comply with Rule 10b5-1 under the Exchange Act, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time.

During the three months ended March 31, 2026, the Company did not repurchase any common shares under the Company's publicly announced program, and there are no other programs under which the Company repurchases shares.

The Company's common share repurchase program activity for the three months ended March 31, 2026 was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Total number of shares purchased** | <br>**Average price paid per share** | **Total number of shares purchased as part of publicly announced program**<sup>(1)</sup> | **Maximum approximate dollar value of shares that may yet be purchased under the program** |
| January 1 through January 31, 2026 |  | $— |  | $250720325 |
| February 1 through February 28, 2026 |  |  |  | 250720325 |
| March 1 through March 31, 2026 |  |  |  | 250720325 |
| Total |  | $— |  |  |
| ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)On June 12, 2017, the Company announced that its Board of Directors approved a $200.0 million share repurchase program for its common shares that would have expired on June 30, 2020, which was subsequently extended through June 30, 2026 and increased in the total share repurchase authority to $500.0 million under the current share repurchase program. As of March 31, 2026, the Company had $250.7 million available under the program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant to a plan intended to comply with Rule 10b5-1 under the Exchange Act, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. No plan or program expired or was terminated during the period covered by this table, and the Company has not determined to terminate the program prior to its expiration.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)On June 12, 2017, the Company announced that its Board of Directors approved a $200.0 million share repurchase program for its common shares that would have expired on June 30, 2020, which was subsequently extended through June 30, 2026 and increased in the total share repurchase authority to $500.0 million under the current share repurchase program. As of March 31, 2026, the Company had $250.7 million available under the program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant to a plan intended to comply with Rule 10b5-1 under the Exchange Act, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. No plan or program expired or was terminated during the period covered by this table, and the Company has not determined to terminate the program prior to its expiration.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)On June 12, 2017, the Company announced that its Board of Directors approved a $200.0 million share repurchase program for its common shares that would have expired on June 30, 2020, which was subsequently extended through June 30, 2026 and increased in the total share repurchase authority to $500.0 million under the current share repurchase program. As of March 31, 2026, the Company had $250.7 million available under the program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant to a plan intended to comply with Rule 10b5-1 under the Exchange Act, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. No plan or program expired or was terminated during the period covered by this table, and the Company has not determined to terminate the program prior to its expiration.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)On June 12, 2017, the Company announced that its Board of Directors approved a $200.0 million share repurchase program for its common shares that would have expired on June 30, 2020, which was subsequently extended through June 30, 2026 and increased in the total share repurchase authority to $500.0 million under the current share repurchase program. As of March 31, 2026, the Company had $250.7 million available under the program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant to a plan intended to comply with Rule 10b5-1 under the Exchange Act, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. No plan or program expired or was terminated during the period covered by this table, and the Company has not determined to terminate the program prior to its expiration.* | ![Image_1.jpg](imax-20260331_g1.jpg)<br>*(1)On June 12, 2017, the Company announced that its Board of Directors approved a $200.0 million share repurchase program for its common shares that would have expired on June 30, 2020, which was subsequently extended through June 30, 2026 and increased in the total share repurchase authority to $500.0 million under the current share repurchase program. As of March 31, 2026, the Company had $250.7 million available under the program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant to a plan intended to comply with Rule 10b5-1 under the Exchange Act, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. No plan or program expired or was terminated during the period covered by this table, and the Company has not determined to terminate the program prior to its expiration.* |

---

During the 2025 Annual General Meeting of IMAX China, shareholders granted its Board of Directors a general mandate authorizing the Board of Directors of IMAX China, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10% of the total number of shares as of June 12, 2025 (33,919,122 shares). This program will be valid until the 2026 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time. During the three months ended March 31, 2026, IMAX China did not repurchase any shares.

(Refer to Note 13 to the Company's audited Consolidated Financial Statements in its 2025 Form 10-K Part I, Item 1 for a summary of the material terms and conditions of the Company's revolving credit facility, which includes a limitation of the amount of permitted share repurchases.)

**Item 5.&nbsp;&nbsp;&nbsp;&nbsp;*Other Information***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(a)***None.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(b)***None.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(c)***None.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**Item 6.&nbsp;&nbsp;&nbsp;&nbsp;*Exhibits***

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | **Description** |
| 31.1\* | <u>[Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated](exhibit311ceocertification.htm)[April](exhibit311ceocertification.htm)[3](exhibit311ceocertification.htm)[0](exhibit311ceocertification.htm)[, 202](exhibit311ceocertification.htm)[6](exhibit311ceocertification.htm)[, by](exhibit311ceocertification.htm)[Ro](exhibit311ceocertification.htm)[bert D. Lister](exhibit311ceocertification.htm)</u> |
| 31.2\* | <u>[Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated](exhibit312cfocertification.htm)[April](exhibit312cfocertification.htm)[3](exhibit312cfocertification.htm)[0](exhibit312cfocertification.htm)[, 202](exhibit312cfocertification.htm)[6](exhibit312cfocertification.htm)[, by Natasha Fernandes](exhibit312cfocertification.htm)</u> |
| 32.1\*\* | <u>[Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated](exhibit321ceocertification.htm)[April](exhibit321ceocertification.htm)[3](exhibit321ceocertification.htm)[0](exhibit321ceocertification.htm)[, 202](exhibit321ceocertification.htm)[6](exhibit321ceocertification.htm)[, by](exhibit321ceocertification.htm)[R](exhibit321ceocertification.htm)[obert D. Lister](exhibit321ceocertification.htm)</u> |
| 32.2\*\* | <u>[Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated](exhibit322cfocertification.htm)[April](exhibit322cfocertification.htm)[3](exhibit322cfocertification.htm)[0](exhibit322cfocertification.htm)[, 202](exhibit322cfocertification.htm)[6](exhibit322cfocertification.htm)[, by Natasha Fernandes](exhibit322cfocertification.htm)</u> |
| 101.INS | Inline XBRL Instance Document – The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.  |
| 101.CAL | Inline XBRL Taxonomy Extension Schema Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101. PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |

---

\*Filed herewith.

\*\*Furnished herewith.

+Management contract or compensatory plan, contract or arrangement.

------

<u>[**Table of Contents**](#id379d5ed014540febbf2b68577b6e60b_7)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | IMAX CORPORATION | IMAX CORPORATION |
| Date: April 30, 2026 | By: | /s/ NATASHA FERNANDES |
|  |  | Natasha Fernandes |
|  |  | Chief Financial Officer & Executive Vice President |
|  |  | (Principal Financial Officer) |
| Date: April 30, 2026 | By: | /s/ JOSE ZLATAR |
|  |  | Jose Zlatar |
|  |  | Senior Vice-President, Finance & Controller |
|  |  | (Principal Accounting Officer) |

---

## Exhibit 31.1

**IMAX CORPORATION**

Exhibit 31.1

**Certification Pursuant to Section 302 of the Sarbanes - Oxley Act of 2002**

I, Robert D. Lister, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 of the registrant, IMAX Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

------

---

| | | | |
|:---|:---|:---|:---|
| Date: | April 30, 2026 | By: | /s/ Robert D. Lister |
|  |  | Name: | Robert D. Lister |
|  |  | Title: | Chief Legal Officer and Senior Executive Vice President (Interim Principal Executive Officer) |

---

## Exhibit 31.2

**IMAX CORPORATION**

Exhibit 31.2

**Certification Pursuant to Section 302 of the Sarbanes - Oxley Act of 2002**

I, Natasha Fernandes, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 of the registrant, IMAX Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | | |
|:---|:---|:---|:---|
| Date: | April 30, 2026 | By: | /s/ Natasha Fernandes |
|  |  | Name: | Natasha Fernandes |
|  |  | Title: | Chief Financial Officer & Executive Vice President |

---

## Exhibit 32.1

**IMAX CORPORATION**

Exhibit 32.1

**CERTIFICATIONS** 

**Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

**(Subsections (A) and (B) of Section 1350, Chapter 63 of Title 18, United States Code)**

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), I, Robert D. Lister, Interim Principal Executive Officer of IMAX Corporation, a Canadian corporation (the "Company"), hereby certify, to my knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the "Form 10-Q") of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | | |
|:---|:---|:---|:---|
| Date: | April 30, 2026 | By: | /s/ Robert D. Lister |
|  |  | Name: | Robert D. Lister |
|  |  | Title: | Chief Legal Officer and Senior Executive Vice President (Interim Principal Executive Officer) |

---

## Exhibit 32.2

**IMAX CORPORATION**

Exhibit 32.2

**CERTIFICATIONS** 

**Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

**(Subsections (A) and (B) of Section 1350, Chapter 63 of Title 18, United States Code)**

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), I, Natasha Fernandes, Chief Financial Officer of IMAX Corporation, a Canadian corporation (the "Company"), hereby certify, to my knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the "Form 10-Q") of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | | |
|:---|:---|:---|:---|
| Date: | April 30, 2026 | By: | /s/ Natasha Fernandes |
|  |  | Name: | Natasha Fernandes |
|  |  | Title: | Chief Financial Officer & Executive Vice President |

---

<br>